<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5869493</article-id><article-id pub-id-type="doi">10.3390/v10030100</article-id><article-id pub-id-type="publisher-id">viruses-10-00100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ajamian</surname><given-names>Lara</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af2-viruses-10-00100">2</xref></contrib><contrib contrib-type="author"><name><surname>Melnychuk</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af2-viruses-10-00100">2</xref></contrib><contrib contrib-type="author"><name><surname>Jean-Pierre</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0656-0714</contrib-id><name><surname>Zaharatos</surname><given-names>Gerasimos J.</given-names></name><xref ref-type="aff" rid="af1-viruses-10-00100">1</xref><xref ref-type="aff" rid="af3-viruses-10-00100">3</xref><xref rid="c1-viruses-10-00100" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-viruses-10-00100"><label>1</label>Lady Davis Institute for Medical Research, Jewish General Hospital, Montr&#x000e9;al, QC H3T 1E2, Canada; <email>lara.ajamian@mail.mcgill.ca</email> (L.A.); <email>luca.melnychuk@mail.mcgill.ca</email> (L.M.); <email>patjp2106@gmail.com</email> (P.J.-P.)</aff><aff id="af2-viruses-10-00100"><label>2</label>Division of Experimental Medicine, Department of Medicine, McGill University, Montr&#x000e9;al, QC H4A 3J1, Canada</aff><aff id="af3-viruses-10-00100"><label>3</label>Division of Infectious Disease, Department of Medicine &#x00026; Division of Medical Microbiology, Department of Clinical Laboratory Medicine, Jewish General Hospital, Montr&#x000e9;al, QC H3T 1E2, Canada</aff><author-notes><corresp id="c1-viruses-10-00100"><label>*</label>Correspondence: <email>gerasimos.zaharatos@mcgill.ca</email>; Tel.: +1-514-340-8294</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>100</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Flagellin&#x02019;s potential as a vaccine adjuvant has been increasingly explored over the last three decades. Monomeric flagellin proteins are the only known agonists of Toll-like receptor 5 (TLR5). This interaction evokes a pro-inflammatory state that impacts upon both innate and adaptive immunity. While pathogen associated molecular patterns (PAMPs) like flagellin have been used as stand-alone adjuvants that are co-delivered with antigen, some investigators have demonstrated a distinct advantage to incorporating antigen epitopes within the structure of flagellin itself. This approach has been particularly effective in enhancing humoral immune responses. We sought to use flagellin as both scaffold and adjuvant for HIV gp41 with the aim of eliciting antibodies to the membrane proximal external region (MPER). Accordingly, we devised a straightforward step-wise approach to select flagellin-antigen fusion proteins for gene-based vaccine development. Using plasmid DNA vector-based expression in mammalian cells, we demonstrate robust expression of codon-optimized full length and hypervariable region-deleted constructs of <italic>Salmonella enterica</italic> subsp. <italic>enterica</italic> serovar <italic>Typhi</italic> flagellin (FliC). An HIV gp41 derived sequence including the MPER (gp41<sub>607&#x02013;683</sub>) was incorporated into various positions of these constructs and the expressed fusion proteins were screened for effective secretion, TLR5 agonist activity and adequate MPER antigenicity. We show that incorporation of gp41<sub>607&#x02013;683</sub> into a FliC-based scaffold significantly augments gp41<sub>607&#x02013;683</sub> immunogenicity in a TLR5 dependent manner and elicits modest MPER-specific humoral responses in a mouse model.</p></abstract><kwd-group><kwd>HIV-1</kwd><kwd>gp41</kwd><kwd>membrane proximal external region</kwd><kwd>MPER</kwd><kwd>flagellin</kwd><kwd>adjuvant</kwd><kwd>DNA vaccine</kwd></kwd-group></article-meta></front><body><sec id="sec1-viruses-10-00100"><title>1. Introduction</title><p>Despite the tremendous success generated by an empiric approach to vaccine development, eliciting robust and long-lasting protective immunity to certain pathogens remains challenging [<xref rid="B1-viruses-10-00100" ref-type="bibr">1</xref>,<xref rid="B2-viruses-10-00100" ref-type="bibr">2</xref>]. While live attenuated virus vaccines have remarkable efficacy, this is not a solution for all pathogens either because they cannot be safely attenuated or because natural infection does not confer protective immunity [<xref rid="B2-viruses-10-00100" ref-type="bibr">2</xref>,<xref rid="B3-viruses-10-00100" ref-type="bibr">3</xref>,<xref rid="B4-viruses-10-00100" ref-type="bibr">4</xref>,<xref rid="B5-viruses-10-00100" ref-type="bibr">5</xref>,<xref rid="B6-viruses-10-00100" ref-type="bibr">6</xref>,<xref rid="B7-viruses-10-00100" ref-type="bibr">7</xref>,<xref rid="B8-viruses-10-00100" ref-type="bibr">8</xref>,<xref rid="B9-viruses-10-00100" ref-type="bibr">9</xref>]. Purified protein or recombinant subunit vaccines have provided a way forward in some instances, however the immunogenicity of such antigens is often poor or vaccination simply does not generate the type of immune response required for protection [<xref rid="B10-viruses-10-00100" ref-type="bibr">10</xref>,<xref rid="B11-viruses-10-00100" ref-type="bibr">11</xref>]. In some instances, the magnitude, longevity or quality of the immune response to such antigens has been improved by using adjuvants, however the mechanism of adjuvant function has been ill-defined for most adjuvants [<xref rid="B10-viruses-10-00100" ref-type="bibr">10</xref>,<xref rid="B11-viruses-10-00100" ref-type="bibr">11</xref>].</p><p>The discovery of pathogen associated molecular patterns (PAMPs), particularly ligands for Toll-like receptors (TLRs) have revolutionized our understanding of innate immunity and ushered in a new era of rational adjuvant development [<xref rid="B10-viruses-10-00100" ref-type="bibr">10</xref>,<xref rid="B12-viruses-10-00100" ref-type="bibr">12</xref>,<xref rid="B13-viruses-10-00100" ref-type="bibr">13</xref>]. One promising avenue of adjuvant research has stemmed from work with the Toll-like receptor 5 (TLR5) ligand flagellin. Polymerized flagellin proteins are the major component of the flagellar apparatus of motile gram-negative and gram-positive bacteria [<xref rid="B14-viruses-10-00100" ref-type="bibr">14</xref>]. Monomeric flagellin proteins are the only known agonists of TLR5 [<xref rid="B15-viruses-10-00100" ref-type="bibr">15</xref>] and a large body of work has explored the interaction between the major <italic>Salmonella</italic> flagellin protein, FliC and TLR5 [<xref rid="B16-viruses-10-00100" ref-type="bibr">16</xref>,<xref rid="B17-viruses-10-00100" ref-type="bibr">17</xref>,<xref rid="B18-viruses-10-00100" ref-type="bibr">18</xref>,<xref rid="B19-viruses-10-00100" ref-type="bibr">19</xref>,<xref rid="B20-viruses-10-00100" ref-type="bibr">20</xref>,<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B22-viruses-10-00100" ref-type="bibr">22</xref>]. TLR5 is expressed on a variety of cells including epithelial cells, monocytes and dendritic cells [<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B23-viruses-10-00100" ref-type="bibr">23</xref>]. Flagellin interacts with TLR5 on the cell surface in a 2:2 complex and induces dimerization of flagellin-TLR5 pairs [<xref rid="B24-viruses-10-00100" ref-type="bibr">24</xref>,<xref rid="B25-viruses-10-00100" ref-type="bibr">25</xref>]. The resulting dimerization of the intracellular TIR domains of TLR5 activate downstream signaling pathways. This includes a MyD88-dependent signalling cascade that culminates in the induction of transcription factors, including NF-&#x003ba;B [<xref rid="B16-viruses-10-00100" ref-type="bibr">16</xref>,<xref rid="B17-viruses-10-00100" ref-type="bibr">17</xref>,<xref rid="B18-viruses-10-00100" ref-type="bibr">18</xref>,<xref rid="B19-viruses-10-00100" ref-type="bibr">19</xref>,<xref rid="B20-viruses-10-00100" ref-type="bibr">20</xref>,<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B22-viruses-10-00100" ref-type="bibr">22</xref>,<xref rid="B26-viruses-10-00100" ref-type="bibr">26</xref>]. In turn, these transcription factors upregulate cytokine transcription and ultimately evoke a pro-inflammatory state.</p><p>Flagellin that gains access to the cytosol is also a trigger for the NAIP&#x02013;NLRC4 inflammasome, where flagellin is sensed by the cytosolic receptor, NAIP5/6 and provokes its interaction with the adapter protein, NLRC4 [<xref rid="B27-viruses-10-00100" ref-type="bibr">27</xref>,<xref rid="B28-viruses-10-00100" ref-type="bibr">28</xref>,<xref rid="B29-viruses-10-00100" ref-type="bibr">29</xref>,<xref rid="B30-viruses-10-00100" ref-type="bibr">30</xref>,<xref rid="B31-viruses-10-00100" ref-type="bibr">31</xref>,<xref rid="B32-viruses-10-00100" ref-type="bibr">32</xref>,<xref rid="B33-viruses-10-00100" ref-type="bibr">33</xref>,<xref rid="B34-viruses-10-00100" ref-type="bibr">34</xref>,<xref rid="B35-viruses-10-00100" ref-type="bibr">35</xref>]. This cascade triggers inflammasome assembly and subsequent caspase-1 activation [<xref rid="B32-viruses-10-00100" ref-type="bibr">32</xref>,<xref rid="B34-viruses-10-00100" ref-type="bibr">34</xref>,<xref rid="B35-viruses-10-00100" ref-type="bibr">35</xref>,<xref rid="B36-viruses-10-00100" ref-type="bibr">36</xref>,<xref rid="B37-viruses-10-00100" ref-type="bibr">37</xref>]. Activated caspase-1 processes several pro-inflammatory cytokines including pro-IL1&#x003b2; and pro-IL-18, thus promoting secretion of their biologically active forms.</p><p>Flagellin has a four-domain structure [<xref rid="B14-viruses-10-00100" ref-type="bibr">14</xref>,<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B38-viruses-10-00100" ref-type="bibr">38</xref>], wherein domains D0 and D1 are formed by interaction between the N-terminal and C-terminal portions of the protein thus producing a stalk-like structure with a concave surface. The central domains D2 and D3 form a cluster emanating at an angle from this stalk (<xref ref-type="fig" rid="viruses-10-00100-f001">Figure 1</xref>). The N and C-termini are critical to flagellin polymerization and certain residue stretches are highly conserved among &#x003b2; and &#x003b3; <italic>Proteobacteria</italic>, whereas the D2 and D3 domains are highly variable among different bacteria [<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B39-viruses-10-00100" ref-type="bibr">39</xref>]. Conserved stretches of the D1 domain contains the key residues engaging with TLR5 and remain sequestered from immune selective pressure while flagellin is in a polymerized state [<xref rid="B24-viruses-10-00100" ref-type="bibr">24</xref>,<xref rid="B40-viruses-10-00100" ref-type="bibr">40</xref>,<xref rid="B41-viruses-10-00100" ref-type="bibr">41</xref>,<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B43-viruses-10-00100" ref-type="bibr">43</xref>]. The C-terminal portion of the D0 domain is also highly conserved and is essential for NAIP-NLRC4 inflammasome triggering [<xref rid="B27-viruses-10-00100" ref-type="bibr">27</xref>,<xref rid="B32-viruses-10-00100" ref-type="bibr">32</xref>,<xref rid="B44-viruses-10-00100" ref-type="bibr">44</xref>]. Conversely, the hypervariable region is exposed on the outside surface of the flagellar apparatus and is a dominant target for humoral responses [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B45-viruses-10-00100" ref-type="bibr">45</xref>,<xref rid="B46-viruses-10-00100" ref-type="bibr">46</xref>,<xref rid="B47-viruses-10-00100" ref-type="bibr">47</xref>].</p><p>Stemming from initial observations of broad and protective immune responses to live attenuated <italic>Salmonella</italic> oral vaccines [<xref rid="B48-viruses-10-00100" ref-type="bibr">48</xref>], it was postulated that such vaccines might prove useful as carriers for heterologous antigens [<xref rid="B49-viruses-10-00100" ref-type="bibr">49</xref>,<xref rid="B50-viruses-10-00100" ref-type="bibr">50</xref>,<xref rid="B51-viruses-10-00100" ref-type="bibr">51</xref>]. Thereafter, the insertion of heterologous epitopes into flagellin to produce a combined antigen-adjuvant module was described in seminal work using either live attenuated <italic>Salmonella</italic> or purified flagellin as the epitope carrier [<xref rid="B52-viruses-10-00100" ref-type="bibr">52</xref>,<xref rid="B53-viruses-10-00100" ref-type="bibr">53</xref>,<xref rid="B54-viruses-10-00100" ref-type="bibr">54</xref>,<xref rid="B55-viruses-10-00100" ref-type="bibr">55</xref>,<xref rid="B56-viruses-10-00100" ref-type="bibr">56</xref>,<xref rid="B57-viruses-10-00100" ref-type="bibr">57</xref>,<xref rid="B58-viruses-10-00100" ref-type="bibr">58</xref>,<xref rid="B59-viruses-10-00100" ref-type="bibr">59</xref>,<xref rid="B60-viruses-10-00100" ref-type="bibr">60</xref>,<xref rid="B61-viruses-10-00100" ref-type="bibr">61</xref>]. Stemming from these initial observations, additional studies have further defined the mechanisms behind the adjuvant effect of flagellin [<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B23-viruses-10-00100" ref-type="bibr">23</xref>] and led to testing of novel vaccine designs in pre-clinical [<xref rid="B62-viruses-10-00100" ref-type="bibr">62</xref>,<xref rid="B63-viruses-10-00100" ref-type="bibr">63</xref>,<xref rid="B64-viruses-10-00100" ref-type="bibr">64</xref>,<xref rid="B65-viruses-10-00100" ref-type="bibr">65</xref>,<xref rid="B66-viruses-10-00100" ref-type="bibr">66</xref>,<xref rid="B67-viruses-10-00100" ref-type="bibr">67</xref>,<xref rid="B68-viruses-10-00100" ref-type="bibr">68</xref>,<xref rid="B69-viruses-10-00100" ref-type="bibr">69</xref>,<xref rid="B70-viruses-10-00100" ref-type="bibr">70</xref>,<xref rid="B71-viruses-10-00100" ref-type="bibr">71</xref>,<xref rid="B72-viruses-10-00100" ref-type="bibr">72</xref>,<xref rid="B73-viruses-10-00100" ref-type="bibr">73</xref>,<xref rid="B74-viruses-10-00100" ref-type="bibr">74</xref>,<xref rid="B75-viruses-10-00100" ref-type="bibr">75</xref>,<xref rid="B76-viruses-10-00100" ref-type="bibr">76</xref>,<xref rid="B77-viruses-10-00100" ref-type="bibr">77</xref>,<xref rid="B78-viruses-10-00100" ref-type="bibr">78</xref>,<xref rid="B79-viruses-10-00100" ref-type="bibr">79</xref>,<xref rid="B80-viruses-10-00100" ref-type="bibr">80</xref>] and clinical studies [<xref rid="B81-viruses-10-00100" ref-type="bibr">81</xref>,<xref rid="B82-viruses-10-00100" ref-type="bibr">82</xref>,<xref rid="B83-viruses-10-00100" ref-type="bibr">83</xref>,<xref rid="B84-viruses-10-00100" ref-type="bibr">84</xref>,<xref rid="B85-viruses-10-00100" ref-type="bibr">85</xref>]. Some have used flagellin as a stand-alone adjuvant that is concurrently delivered with antigen [<xref rid="B86-viruses-10-00100" ref-type="bibr">86</xref>,<xref rid="B87-viruses-10-00100" ref-type="bibr">87</xref>,<xref rid="B88-viruses-10-00100" ref-type="bibr">88</xref>,<xref rid="B89-viruses-10-00100" ref-type="bibr">89</xref>], whereas other studies have demonstrated a distinct advantage to incorporating heterologous epitopes within the structure of flagellin itself at either the N or C-terminus or within the hypervariable region [<xref rid="B72-viruses-10-00100" ref-type="bibr">72</xref>,<xref rid="B73-viruses-10-00100" ref-type="bibr">73</xref>]. Flagellin mediated enhancement of humoral responses appears to require stimulation of TLR5-expressing dendritic cells with subsequent activation of antigen-specific CD4 T-cells [<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B23-viruses-10-00100" ref-type="bibr">23</xref>,<xref rid="B26-viruses-10-00100" ref-type="bibr">26</xref>,<xref rid="B73-viruses-10-00100" ref-type="bibr">73</xref>,<xref rid="B86-viruses-10-00100" ref-type="bibr">86</xref>,<xref rid="B90-viruses-10-00100" ref-type="bibr">90</xref>,<xref rid="B91-viruses-10-00100" ref-type="bibr">91</xref>]. The TLR5-MyD88 or NAIP-NLRC4 pathway dependence of these adjuvant effects has clearly been demonstrated [<xref rid="B21-viruses-10-00100" ref-type="bibr">21</xref>,<xref rid="B23-viruses-10-00100" ref-type="bibr">23</xref>,<xref rid="B33-viruses-10-00100" ref-type="bibr">33</xref>,<xref rid="B72-viruses-10-00100" ref-type="bibr">72</xref>,<xref rid="B91-viruses-10-00100" ref-type="bibr">91</xref>] but some work has raised the possibility that flagellin may also enhance immune responses via alternate mechanisms [<xref rid="B92-viruses-10-00100" ref-type="bibr">92</xref>,<xref rid="B93-viruses-10-00100" ref-type="bibr">93</xref>,<xref rid="B94-viruses-10-00100" ref-type="bibr">94</xref>,<xref rid="B95-viruses-10-00100" ref-type="bibr">95</xref>].</p><p>For the majority of licensed vaccines, prevention of infection correlates with the induction of pathogen-specific antibodies [<xref rid="B96-viruses-10-00100" ref-type="bibr">96</xref>,<xref rid="B97-viruses-10-00100" ref-type="bibr">97</xref>]. In the context of viral infection, neutralizing antibodies block interaction of the virus with target receptors on host cells and prevent entry and thus subsequent replication. Despite the recent discovery of a great number of potent HIV-1 envelope-specific broadly neutralizing antibodies, an inability to elicit such antibodies through immunization continues to hinder the HIV vaccine discovery enterprise [<xref rid="B98-viruses-10-00100" ref-type="bibr">98</xref>,<xref rid="B99-viruses-10-00100" ref-type="bibr">99</xref>].</p><p>The HIV gp41 membrane proximal external region (MPER) represents one important but formidable target for HIV-1 vaccine development. The MPER is a highly conserved region targeted by broadly neutralizing antibodies (bnAbs) [<xref rid="B100-viruses-10-00100" ref-type="bibr">100</xref>]. Although such MPER-specific antibodies have been shown to prevent infection through passive immunization [<xref rid="B101-viruses-10-00100" ref-type="bibr">101</xref>,<xref rid="B102-viruses-10-00100" ref-type="bibr">102</xref>,<xref rid="B103-viruses-10-00100" ref-type="bibr">103</xref>], numerous animal studies have failed to elicit robust or sufficiently broad neutralizing antibody responses using a variety of strategies [<xref rid="B104-viruses-10-00100" ref-type="bibr">104</xref>,<xref rid="B105-viruses-10-00100" ref-type="bibr">105</xref>,<xref rid="B106-viruses-10-00100" ref-type="bibr">106</xref>,<xref rid="B107-viruses-10-00100" ref-type="bibr">107</xref>,<xref rid="B108-viruses-10-00100" ref-type="bibr">108</xref>,<xref rid="B109-viruses-10-00100" ref-type="bibr">109</xref>,<xref rid="B110-viruses-10-00100" ref-type="bibr">110</xref>,<xref rid="B111-viruses-10-00100" ref-type="bibr">111</xref>,<xref rid="B112-viruses-10-00100" ref-type="bibr">112</xref>,<xref rid="B113-viruses-10-00100" ref-type="bibr">113</xref>,<xref rid="B114-viruses-10-00100" ref-type="bibr">114</xref>]. Issues hindering the development of gp41 MPER as a vaccine target include poor immunogenicity due in part to steric hindrance and lack of accessibility [<xref rid="B100-viruses-10-00100" ref-type="bibr">100</xref>,<xref rid="B115-viruses-10-00100" ref-type="bibr">115</xref>], hydrophobicity that renders the MPER prone to aggregation in solution [<xref rid="B116-viruses-10-00100" ref-type="bibr">116</xref>], immunodominance of adjacent gp41 regions lacking any neutralizing epitopes [<xref rid="B117-viruses-10-00100" ref-type="bibr">117</xref>,<xref rid="B118-viruses-10-00100" ref-type="bibr">118</xref>] and the apparent auto-reactivity of MPER-specific bnAbs towards cell membrane lipids [<xref rid="B119-viruses-10-00100" ref-type="bibr">119</xref>,<xref rid="B120-viruses-10-00100" ref-type="bibr">120</xref>].</p><p>Considering these challenges, we sought to use flagellin as both scaffold and adjuvant for HIV gp41, with the aim of eliciting antibodies to the MPER. We chose to pursue a gene-based vaccine approach, aiming to provide future capacity to both develop platforms that could express proteins with mammalian glycosylation and conduct iterative research with different DNA and viral vector platforms, two parameters which will likely be key to developing a protective HIV vaccine. We devised a straightforward step-wise approach to select FliC-antigen fusion proteins for gene-based vaccine development. Accordingly, we generated plasmid DNA vaccine vectors encoding a variety of FliC-HIV gp41 fusion proteins and screened candidate vaccines based on adequate mammalian cell expression, fusion protein secretion, TLR5 agonist activity and gp41 MPER antigenicity. Insertion of a gp41-derived sequence at different positions within FliC led to a broad spectrum of outcomes with regard to secretion and agonist activity. Utilizing this multi-modal process, we selected a promising vaccine candidate that fulfilled all our screening criteria. We demonstrate that this FliC-HIV gp41 DNA vaccine candidate was highly immunogenic relative to a DNA vaccine encoding gp41 alone, eliciting modest MPER-specific humoral immunogenicity. Moreover, the augmented immunogenicity of the vaccine was TLR5-dependant.</p></sec><sec id="sec2-viruses-10-00100"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-10-00100"><title>2.1. Construction of FliC and HIV-1 gp41 Expression Vectors</title><p>All flagellin (FliC) and gp41 gene constructs described were codon optimized and synthesized using the GENEART platform (<uri xlink:href="http://www.lifetechnologies.com/ca/en/home/life-science/cloning/gene-synthesis/geneart-gene-synthesis/geneoptimizer.html">http://www.lifetechnologies.com/ca/en/home/life-science/cloning/gene-synthesis/geneart-gene-synthesis/geneoptimizer.html</uri>) (Life Technologies, Carlsbad, CA, USA). To produce a mammalian cell expressed FliC, we used an amino acid sequence identical to that of <italic>Salmonella enterica</italic> subsp. <italic>enterica</italic> serovar <italic>Typhi</italic> flagellin (GenBank: AAA27067.1). Numbering of FliC residues in our constructs was based on a previously established numbering convention [<xref rid="B18-viruses-10-00100" ref-type="bibr">18</xref>]. We previously described generating a Clade C gp41 ectodomain consensus sequence [<xref rid="B121-viruses-10-00100" ref-type="bibr">121</xref>]. Based on this sequence we subsequently selected a shorter sequence corresponding to the gp41 ectodomain spanning amino acids 607 to 683 in gp160 (according to HxB2 numbering), herein referred to as gp41<sub>607&#x02013;683</sub> (see <xref ref-type="app" rid="app1-viruses-10-00100">Supplementary Methods 1</xref>). For all gene constructs, a tPA signal sequence [<xref rid="B122-viruses-10-00100" ref-type="bibr">122</xref>] was added synthetically to the N-terminus and a GGGS linker and 3XFLAG tag were added to the C-terminus. For constructs used to produce coating antigen for antibody binding assays, a Twin-Strep-Tag was also added C-terminal to the 3XFLAG tag. Synthesized genes were cloned into the pVAX plasmid using BamHI and NotI enzymes. Deletion and point mutants and fusion constructs were generated using the Seamless Cloning Kit (Life Technologies, Carlsbad, CA, USA). The following constructs were created: gp41<sub>607&#x02013;671</sub> (lacking the twelve most C-terminal residues making up the MPER), FliC R90D, FliC &#x00394;89&#x02013;96, FliC &#x00394;174&#x02013;400, FliC &#x00394;220&#x02013;320, FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400, FliC &#x00394;89&#x02013;96 &#x00394;220&#x02013;320, gp41<sub>607&#x02013;683</sub> FliC &#x00394;174&#x02013;400, gp41<sub>607&#x02013;683</sub> FliC &#x00394;220&#x02013;320, FliC &#x00394;174-[gp41<sub>607&#x02013;683</sub>]-400, FliC &#x00394;220-[gp41<sub>607&#x02013;683</sub>]-320, FliC gp41<sub>607&#x02013;683</sub>, FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>, FliC &#x00394;220&#x02013;320 gp41<sub>607&#x02013;683</sub> and FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>. All plasmid DNA expression vectors used in downstream transfection or vaccination experiments were prepared using a Qiagen EndoFree Plasmid kit (Qiagen, Hamburg, Germany).</p></sec><sec id="sec2dot2-viruses-10-00100"><title>2.2. Cell Culture</title><p>HEK 293T cells (CRL-3216; ATCC, Manassas, VA, USA) and the mouse monocyte/macrophage cell line J774A.1 (TIB-67; ATCC, Manassas, VA, USA) were each cultured in Dulbecco&#x02019;s Minimal Essential Media (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 10 mM HEPES, 100 U/mL penicillin and 100 &#x003bc;g/mL streptomycin (all from Corning, Tewksbury, MA, USA). The human monocyte cell line, THP-1 (TIB-202; ATCC, Manassas, VA, USA) was cultured in RPMI-1640 and the same supplements as well as 0.05 mM 2-mercaptoethanol (Sigma, St Louis, MO, USA). HEK-Blue-hTLR5 cells (Invivogen, San Diego, CA, USA) were cultured in Dulbecco&#x02019;s Minimal Essential Media (DMEM) supplemented with 10% FBS, 10 mM HEPES, 50 U/mL penicillin, 50 &#x003bc;g/mL streptomycin, 30 &#x003bc;g/mL blasticidin and 100 &#x003bc;g/mL zeocin (the latter two reagents from Invivogen, San Diego, CA, USA). All cells were cultured at 37 &#x000b0;C and 5% CO<sub>2</sub> in a humidified incubator.</p></sec><sec id="sec2dot3-viruses-10-00100"><title>2.3. Transfection and Cell Lysate/Supernatant Preparation</title><p>HEK 293T cells were seeded at 3 &#x000d7; 10<sup>6</sup> cells/well in a 6 well plate 24 h prior to transfection. JetPEI (Polyplus, Illkirch, France) was used for transient transfection of 293T cells. Media was changed 24 h after transfection to DMEM supplemented with 1% FBS but otherwise constituted as above. Cell lysates and supernatants were collected 48 h after transfection. Cells were washed twice with phosphate-buffered saline (PBS) and spun down at 300 g for 10 min. Cells were lysed in NP40 cell lysis buffer (Life Technologies, Carlsbad, CA, USA) containing a protease inhibitor cocktail (Sigma, St Louis, MO, USA). Cells supernatants were clarified by centrifugation for 15 min at 16,000 g. Cell lysates and clarified supernatants were stored at &#x02212;20 &#x000b0;C until analyzed.</p></sec><sec id="sec2dot4-viruses-10-00100"><title>2.4. SDS-PAGE, Immunoblotting and Deglycosylation Studies</title><p>All SDS-PAGE and immunoblotting reagents and devices were from the same manufacturer (Life Technologies, Carlsbad, CA, USA), unless otherwise stated. All procedures were carried out as previously described [<xref rid="B121-viruses-10-00100" ref-type="bibr">121</xref>]. Cell lysates and supernatants were incubated at 70 &#x000b0;C for 10 min after the addition of 4X LDS Loading Buffer and Reducing Agent. Samples were run on NuPAGE 4&#x02013;12% Bis-Tris gels at 150 V under reducing conditions. Gels were transferred to PVDF membranes using the iBlot transfer device. Membranes were blocked for 20 min in 10% non-fat dry milk dissolved in Tris-buffered saline containing 0.05% Tween (TBS-T). Resolved proteins were detected by blotting with a mouse anti-FLAG tag antibody, clone M2 (Sigma, St. Louis, MO, USA) diluted to 0.5 &#x003bc;g/mL in 3% milk TBS-T or a mouse anti-Tubulin antibody, clone B3 (Thermo Scientific, Waltham, MA, USA) diluted to 1:2500 in 1% milk TBS-T. A secondary goat anti-mouse IgG antibody conjugated to alkaline phosphatase (AP) was diluted to 1:5000 in TBS-T and used to detect the primary antibody. CDP-star substrate was used to generate a chemiluminescent signal, which was detected using X-ray film (VWR, Radnor, PA, USA) and an X-ray imager (Kodak, Rochester, NY, USA). In deglycosylation studies, we used PNGase F (NEB, Ipswich, MA, USA) to remove N-glycans from proteins of interest, secreted into cell supernatants. Cell supernatants at a volume of 13.5 &#x003bc;L were incubated with 1.5 &#x003bc;L of glycoprotein denaturing buffer (NEB, Ipswich, MA, USA) for 10 min at 99 &#x000b0;C. Samples were then treated with 1 &#x003bc;L PNGase F for 1 h at 37 &#x000b0;C in the presence of 2 &#x003bc;L NP-40 and 2 &#x003bc;L G7 buffer (NEB, Ipswich, MA, USA).</p></sec><sec id="sec2dot5-viruses-10-00100"><title>2.5. Secretion ELISA</title><p>Cell supernatants (100 &#x003bc;L per well) were applied to anti-FLAG tag antibody-coated plates (GenScript, Piscataway, NJ, USA) and incubated for 1 h at room temperature (RT). Plates were subsequently washed three times with PBS-T, then incubated with a mouse anti-FLAG tag antibody conjugated to horseradish peroxidase (HRP) (Sigma, St. Louis, MO, USA) at a 1:20,000 dilution for 1 h at RT. After incubation, plates were washed three times and relative amounts of secreted protein were detected using the QuantaRed substrate system (Thermo Scientific, Waltham, MA, USA). Data were collected as relative fluorescence units (RFU) using a fluorescence plate reader with an excitation/emission filter of 544 nm/612 nm. The relative level of secreted FLAG-tagged protein determined by this secretion ELISA was used to normalize input for the TLR5 agonist activity and antibody binding assays described below.</p></sec><sec id="sec2dot6-viruses-10-00100"><title>2.6. TLR5 Agonist Activity Assays</title><sec id="sec2dot6dot1-viruses-10-00100"><title>2.6.1. HEK-Blue-hTLR5</title><p>A cell suspension of 140,000 cells/mL of HEK-Blue-hTLR5 was prepared and 180 &#x003bc;L was plated in each well of a 96-well plate containing 20 &#x003bc;L of a 1:100 dilution of previously normalized supernatants containing flagellin proteins. HEK-Blue-hTLR5 cell suspensions used were produced by scraping and dissociation by gentle pipetting. Cell culture supernatants were normalized based on the relative amounts of secreted protein determined by the secretion ELISA (described above). Treated HEK-Blue-hTLR5 cells were incubated for 20 h prior to determining the quantity of secreted embryonic alkaline phosphatase (SEAP) released into the supernatant using the QUANTI-Blue colorimetric enzyme assay (Invivogen, San Diego, CA, USA) as per manufacturer&#x02019;s instructions. Briefly, 5 &#x003bc;L of treated HEK-Blue-hTLR5 supernatant from each condition was added to 200 &#x003bc;L of QUANTI-Blue reagent. After one hour incubation at 37 &#x000b0;C, SEAP was quantified by measuring absorbance at 655 nm. Relative quantities, presented as response ratios, were calculated by dividing the absorbance of each condition by the absorbance of the control condition.</p></sec><sec id="sec2dot6dot2-viruses-10-00100"><title>2.6.2. Transcriptional Activation of IL-1&#x003b2; in Monocyte/Macrophage Cell Lines</title><p>A cell suspension of 140,000 cells/mL of either THP-1 or J774A.1 cells was prepared then 180 &#x003bc;L was transferred to wells of a 96-well plate. Subsequently, 20 &#x003bc;L of a 1:100 dilution of previously normalized supernatants containing flagellin proteins was added to each well. J774A.1 cell suspensions used were produced by scraping and dissociation by gentle pipetting. LPS (Invivogen, San Diego, CA, USA) diluted in culture medium at a final concentration of 1 &#x003bc;g/mL was used as a positive control. Empty vector-transfected cell supernatant was used as a negative control. Treated cells were incubated for 2 h then harvested and RNA was extracted using an RNeasy mini kit (Qiagen, Valencia, CA, USA) with on-column DNase digestion as per the manufacturer&#x02019;s instructions. Eluted RNA was used in a two-step RT-PCR reaction, utilizing the SuperScript IV First-Strand Synthesis System and Platinum Hot Start PCR Master Mix (both from Life Technologies, Carlsbad, CA, USA) as per the manufacturer&#x02019;s instructions. Random hexamers were used in reverse transcription and the following primers were used for PCR: il1beta forward 5&#x02032;-TGTAATGAAAGACGGCACACC-3&#x02032;; il1beta reverse 5&#x02032;-TCTTCTTTGGGTATTGCTTGG-3&#x02032;; gapdh forward 5&#x02032;-AGCTTGTCATCAACGGGAAG-3&#x02032;; gapdh reverse 5&#x02032;-TTTGATGTTAGTGGGGTCTCG-3&#x02032;. RT-PCR products underwent agarose gel electrophoresis and were stained with SYBR Safe DNA Gel Stain (Life Technologies, Carlsbad, CA, USA) then visualized with a blue-light transilluminator.</p></sec></sec><sec id="sec2dot7-viruses-10-00100"><title>2.7. ELISA to Detect Binding by Monoclonal bnAb</title><p>To assess bnAb binding to secreted gp41<sub>607&#x02013;683</sub> or FliC gp41<sub>607&#x02013;683</sub> proteins, cell supernatants were diluted in DMEM according to the relative level of gp41 determined by the secretion ELISA as previously described [<xref rid="B121-viruses-10-00100" ref-type="bibr">121</xref>], then plated on streptavidin coated plates (Thermo Scientific, Waltham, MA, USA) for 1 h at RT and subsequently washed three times with PBS-T. Each gp41 antigen was synthetically linked to a 3XFLAG and Twin-Strep-Tag at its C-terminus. The following HIV-1 gp41 monoclonal antibody reagents were generously provided by investigators via the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 4E10 (from Dr. Hermann Katinger) and 10E8 (from Dr. Mark Connors). Each bnAb was diluted to 1 &#x003bc;g/mL in 100 &#x003bc;L of PBS-T containing 5% bovine serum albumin (BSA), then applied to wells and allowed to bind for 1 h at RT. Plates were washed three times and bnAb binding was probed using a mouse anti-human IgG AP-conjugated antibody (Life Technologies, Carlsbad, CA, USA) diluted 1:5000 in PBS-T containing 5% BSA for 1 h at RT. Plates were then washed three times, AttoPhos fluorescent substrate (Promega, Fitchburg, WI, USA) was applied to wells and the plate was incubated for 15 min at RT. Data were collected as relative fluorescence units (RFU) using a fluorescence plate reader with an excitation/emission filter of 485 nm/520 nm. Results were normalized to levels of secreted protein captured in each well using an HRP-conjugated anti-FLAG tag antibody and QuantaRed substrate as described above.</p></sec><sec id="sec2dot8-viruses-10-00100"><title>2.8. Mice and Immunizations</title><p>All procedures were approved by the institutional Animal Care Committee of McGill University (Protocol #2012-7237 JGH; first approval date: 01/01/2013). Guidelines and regulations established by the Canadian Council on Animal Care were adhered to and all experiments complied with ARRIVE guidelines. Six-week-old female BALB/c mice were obtained from Charles River Laboratories (Montr&#x000e9;al, QC, Canada) and housed under pathogen-free conditions. Mice were injected with 50 &#x003bc;g of DNA in each <italic>tibialis anterior</italic> muscle (50 &#x003bc;L at a concentration of 1 &#x003bc;g/&#x003bc;L in sterile normal saline) with either empty vector negative control (pVAX) or one of three DNA vaccines (gp41<sub>607&#x02013;683</sub>, FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>). Mice were immunized with DNA vaccines either two or four times, depending on the experiment, at two week intervals. Blood was collected 2 weeks after the last immunization. Whole blood was allowed to clot for 1 h at room temperature then spun down at 2000 g for 15 min. Sera were then collected and stored at &#x02212;80 &#x000b0;C until analysis.</p></sec><sec id="sec2dot9-viruses-10-00100"><title>2.9. ELISA to Detect Mouse Anti-gp41 IgG Response</title><p>Streptavidin-coated (Roche, Basel, Switzerland) or Strep-Tactin-coated plates (IBA Life Sciences, Goettingen, Germany) were coated with either gp41<sub>607&#x02013;683</sub> or gp41<sub>607&#x02013;671</sub> overnight at 4 &#x000b0;C. Each gp41 antigen was synthetically linked to a 3XFLAG and Twin-Strep-Tag at its C-terminus. Antigen was coated onto plates from clarified supernatants diluted to a concentration of 2 &#x003bc;g/&#x003bc;L of the protein of interest. The concentration was determined by ELISA and a standard of FLAG tag immunoprecipitation-purified gp41 as previously described [<xref rid="B121-viruses-10-00100" ref-type="bibr">121</xref>]. Coated plates were washed three times with PBS-T containing 0.01% BSA. Serum from each mouse was serially diluted up to 1:200 (see <xref ref-type="app" rid="app1-viruses-10-00100">Supplementary Methods 2</xref>) in PBS-T containing 0.01% BSA, applied to the plates and incubated for 2 h at room temperature. For experiments assessing MPER specificity of humoral response, sera from the FliC&#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> vaccinated group were pooled prior to dilution and processed as described above. Plates were washed three times and antibody binding was probed using a goat anti-mouse IgG AP-conjugated antibody (Life Technologies, Carlsbad, CA, USA) diluted to 1:5000 in PBS-T containing 0.01% BSA. Plates were incubated for 1 h, then washed three times. The bound AP-conjugated secondary antibody was detected using the ELISA Amplification System (Life Technologies, Carlsbad, CA, USA) as per manufacturer&#x02019;s instruction. Plates were read on an ELISA plate reader at an absorbance of 495 nm. An independent two sample t-test was used to determine statistical significance between experimental arms.</p></sec></sec><sec id="sec3-viruses-10-00100"><title>3. Results</title><sec id="sec3dot1-viruses-10-00100"><title>3.1. Codon-Optimized Salmonella enterica Subsp. enterica Serovar Typhi FliC Can Be Expressed in and Effectively Secreted from Mammalian Cells</title><p>We first set out to determine if the FliC gene could be well expressed and effectively secreted by plasmid DNA vector-transfected cells. We produced mammalian codon-optimized FliC and inserted it into a CMV promoter driven expression plasmid (pVAX). As the hypervariable region of FliC has been shown to be a dominant antigenic region [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B47-viruses-10-00100" ref-type="bibr">47</xref>] that is not necessary for TLR5 agonist function, we also generated 2 hypervariable region deletion mutants of FliC, one lacking residues 174&#x02013;400 (FliC &#x00394;174&#x02013;400) and another lacking residues 220&#x02013;320 (FliC &#x00394;220&#x02013;320) (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>A) and inserted them into the same backbone vector. Similar deletion mutants have previously been described [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B47-viruses-10-00100" ref-type="bibr">47</xref>]. After transfection of 293T cells, we gauged the level of expression and secretion using both immunoblotting and ELISA-based methods. We observed robust expression of our three FliC variants in cell lysates (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>B), however we also visualized a ladder of products migrating below the predicted size of protein variants suggesting that a portion of the expressed proteins underwent proteolytic cleavage. Moreover, while the predicted molecular weight for full length FliC is approximately 60 kDa, the largest and most abundant protein observed in our lysates migrated at approximately 80 kDa. Similar results were observed for our deletion mutants (FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320), with the largest band migrating at a higher molecular mass then predicted. In corresponding supernatants, protein bands at or above the predicted molecular weight were also observed (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>B). These findings suggested that the FliC variant, particularly the secreted forms, had undergone extensive glycosylation. Indeed, flagellin is glycosylated in bacterial systems [<xref rid="B123-viruses-10-00100" ref-type="bibr">123</xref>]. It has also been previously shown that baculovirus encoded FliC undergoes N-linked glycosylation when expressed in insect cells (<italic>Spodoptera frugiperda</italic> Sf9) [<xref rid="B78-viruses-10-00100" ref-type="bibr">78</xref>]. In silico analysis revealed that the FliC amino acid sequence we utilized contains at least four asparagine residues predicted to be N-glycosylated (<uri xlink:href="http://www.cbs.dtu.dk/services/NetNGlyc/">http://www.cbs.dtu.dk/services/NetNGlyc/</uri> and <xref ref-type="app" rid="app1-viruses-10-00100">Figure S1</xref>). To address this possibility, supernatants were treated with PNGase F to remove N-linked glycosylations. Treatment with PNGase F resulted in the disappearance of the higher molecular mass proteins and visualization of proteins of the predicted size for all three FliC variants (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>B), thus confirming that FliC is glycosylated when expressed in a mammalian system. A shift in molecular weight upon PNGase treatment was also observed in cell lysates for all three proteins (<xref ref-type="app" rid="app1-viruses-10-00100">Figure S2</xref>). Of the three FliC variants, full length FliC appeared to be the most highly expressed and secreted (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>B). To better estimate the relative degree of secretion of each variant, an ELISA-based assay was used to measure the FLAG-tagged secreted proteins in culture supernatants. All FliC variants were readily detectable, however relative to full length FliC, FliC&#x00394;174&#x02013;400 and especially FliC&#x00394;220&#x02013;320 exhibited diminished secretion (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>C).</p></sec><sec id="sec3dot2-viruses-10-00100"><title>3.2. Mammalian Cell-Expressed and Secreted FliC Retains TLR5 Agonist Activity</title><p>Next, we sought to ascertain whether mammalian expressed FliC maintained TLR5 agonist activity. To this end, we applied transfected cell culture supernatants containing either full length FliC, FliC &#x00394;174&#x02013;400 or FliC &#x00394;220&#x02013;320 to HEK-Blue-hTLR5 cells, a TLR5 agonist activity indicator cell. Full length FliC and FliC &#x00394;174&#x02013;400 demonstrated robust TLR5 agonist activity, however FliC &#x00394;220&#x02013;320 only elicited a minor response (<xref ref-type="fig" rid="viruses-10-00100-f002">Figure 2</xref>D).</p><p>To further confirm that our FliC variants were indeed signaling through TLR5, we sought to modify residues in FliC that are necessary for TLR5 agonist activity. Residues 89&#x02013;96 (QRVRELAV), in the D1 domain of FliC, are required for FliC TLR5 agonist function [<xref rid="B41-viruses-10-00100" ref-type="bibr">41</xref>,<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>]. We therefore produced deletion mutants of this region (&#x00394;89&#x02013;96) in full length FliC, FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320 (<xref ref-type="fig" rid="viruses-10-00100-f003">Figure 3</xref>A). All &#x00394;89&#x02013;96 constructs were expressed and secreted to a similar extent as their parent constructs (<xref ref-type="fig" rid="viruses-10-00100-f003">Figure 3</xref>B). No TLR5 agonist activity was observed with any construct containing the &#x00394;89&#x02013;96 deletion as compared to their parental constructs and in fact their responses were no different than that produced by the empty vector control construct (<xref ref-type="fig" rid="viruses-10-00100-f003">Figure 3</xref>C). This confirmed that the responses produced by the indicator cell line upon exposure to FliC, FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320 were dependent on the TLR5 agonist activity of FliC.</p><p>Having confirmed TLR5 agonist activity for our FliC variants using HEK-Blue-hTLR5 cells, we then wished to gauge their capacity for triggering a signaling cascade via TLR5 in a more biologically relevant system. To this end we used monocyte cell lines THP-1 (human) and J774A.1 (mouse). These cell lines express TLR5 on their surface and engagement of TLR5 by flagellin would activate signaling pathways that would ultimately lead to the transcriptional upregulation of pro-inflammatory cytokines [<xref rid="B124-viruses-10-00100" ref-type="bibr">124</xref>,<xref rid="B125-viruses-10-00100" ref-type="bibr">125</xref>]. Accordingly, we exposed these cells to either full length FliC, FliC &#x00394;89&#x02013;96 or full-length FliC containing the point mutation R90D (FliC R90D). Mutations at position R90 in FliC have been previously shown to diminish or abrogate signaling via mouse or human TLR5, respectively [<xref rid="B18-viruses-10-00100" ref-type="bibr">18</xref>,<xref rid="B126-viruses-10-00100" ref-type="bibr">126</xref>,<xref rid="B127-viruses-10-00100" ref-type="bibr">127</xref>,<xref rid="B128-viruses-10-00100" ref-type="bibr">128</xref>].</p><p>Focusing on one such cytokine, IL-1&#x003b2;, we compared the relative abundance of IL-1&#x003b2; transcripts in THP-1 or J774A.1 cells after exposure to either full length FliC, FliC R90D or FliC &#x00394;89&#x02013;96. In parallel, cells were also exposed to either positive or negative control conditions using LPS or supernatant from empty vector-transfected cells, respectively. In THP-1 cells, full length FliC and LPS clearly induced IL-1&#x003b2; (<xref ref-type="fig" rid="viruses-10-00100-f003">Figure 3</xref>D). FliC R90D and FliC &#x00394;89&#x02013;96 failed to induce any IL-1&#x003b2; beyond the basal level present in our negative control conditions. Results with J774A.1 cells were similar except that FliC R90D retained its ability to induce IL-1&#x003b2; (<xref ref-type="fig" rid="viruses-10-00100-f003">Figure 3</xref>D). The difference in intra-species sensitivity to FliC R90 mutant agonist activity was in keeping with previously published work [<xref rid="B126-viruses-10-00100" ref-type="bibr">126</xref>,<xref rid="B127-viruses-10-00100" ref-type="bibr">127</xref>,<xref rid="B128-viruses-10-00100" ref-type="bibr">128</xref>]. Overall, these experiments further confirmed that mammalian cell expressed FliC variants can trigger a signaling cascade via TLR5.</p></sec><sec id="sec3dot3-viruses-10-00100"><title>3.3. Adding gp41 MPER (gp41<sub>607&#x02013;683</sub>) to the C Terminus of FliC&#x00394;174&#x02013;400 Results in a Secreted Protein that Maintains TLR5 Agonist Activity</title><p>We next sought to use FliC as both a scaffold and adjuvant for HIV gp41. To determine the optimal position to insert gp41 (amino acids 605&#x02013;683, gp41<sub>607&#x02013;683</sub> herein), we generated eight different constructs wherein gp41<sub>607&#x02013;683</sub> was inserted at the amino- or carboxy-terminus of full length FliC, FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320, or alternatively within the remaining hypervariable regions of FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320 (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>A). All proteins were expressed and secreted to varying degrees as observed by immunoblotting (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>B). An ELISA-based assay was once again used to measure the secreted proteins in culture supernatants (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>C). The level of secretion varied widely among the different constructs. Relative to full length FliC, gp41<sub>607&#x02013;683</sub> insertion at the amino-terminus or within the hypervariable region of FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320 variants resulted in an increase in protein secretion (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>C). Insertion of gp41<sub>607&#x02013;683</sub> at the carboxy-terminus produced variants that were poorly secreted except for the FliC &#x00394;174&#x02013;400 variant.</p><p>Having gauged the relative secretion levels of our constructs, we next sought to determine if they were able to maintain TLR5 agonist activity. Despite their superior propensity for secretion, once normalized for the relative amount of secreted protein, FliC variants with gp41<sub>607&#x02013;683</sub> inserted at the amino-terminus or within the hypervariable regions of FliC &#x00394;174&#x02013;400 and FliC &#x00394;220&#x02013;320, manifested weaker TLR5 agonist activity relative to their parent constructs (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>D). Instead we observed that insertion of gp41<sub>607&#x02013;683</sub> at the carboxy-terminus preserved TLR5 agonist activity to a greater degree.</p></sec><sec id="sec3dot4-viruses-10-00100"><title>3.4. Adding gp41 MPER (gp41<sub>607&#x02013;683</sub>) to the C Terminus of FliC&#x00394;174&#x02013;400 Maintains gp41 Antigenicity</title><p>As we wished to minimize humoral responses to the FliC hypervariable region, and FliC &#x00394;174&#x02013;400 produced superior TLR5 agonist activity compared to FliC &#x00394;220&#x02013;320 (<xref ref-type="fig" rid="viruses-10-00100-f004">Figure 4</xref>D), we chose to pursue the development FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> as a DNA vaccine candidate. FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>, FliC &#x00394;174&#x02013;400 and gp41<sub>607&#x02013;683</sub> were readily detectable in transiently transfected cell lysates and treatment of lysates with PNGase allowed better visualization of each protein (<xref ref-type="fig" rid="viruses-10-00100-f005">Figure 5</xref>A). Immunoblotting also allowed us to readily detect secreted proteins although gp41<sub>607&#x02013;683</sub> was only detectable after PNGase treatment (<xref ref-type="fig" rid="viruses-10-00100-f005">Figure 5</xref>A). To test if FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> maintained gp41 antigenicity, we next sought to ascertain if this protein was bound by the bNAbs 10E8 and 4E10 (<xref ref-type="fig" rid="viruses-10-00100-f005">Figure 5</xref>B) as compared to positive (gp41<sub>607&#x02013;683</sub> in the absence of flagellin) and negative (FliC &#x00394;174&#x02013;400) control proteins. Our experiments revealed that FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> was bound by 10E8 and 4E10, albeit to a lesser degree than gp41<sub>607&#x02013;683</sub> (<xref ref-type="fig" rid="viruses-10-00100-f005">Figure 5</xref>C), thus demonstrating preservation of gp41 antigenicity.</p></sec><sec id="sec3dot5-viruses-10-00100"><title>3.5. FliC Augments gp41<sub>607&#x02013;683</sub> Immunogenicity and Elicits MPER-Specific Humoral Responses</title><p>Having determined that FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> retained gp41 antigenicity, we then proceeded to gauge the immunogenicity of the expressed protein in the context of a DNA vaccine. Mice were immunized with one of three DNA vaccines: pVAX (empty vector control), gp41<sub>607&#x02013;683</sub> or FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>. Mice were immunized on days 0, 14, 28 and 42 and blood was collected 2 weeks post the fourth immunization. We then measured gp41-specific IgG responses by ELISA (<xref ref-type="fig" rid="viruses-10-00100-f006">Figure 6</xref>A). For the majority of the mice who received FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>, strong responses were detectable out to a 1/200 dilution of serum (<xref ref-type="fig" rid="viruses-10-00100-f006">Figure 6</xref>A). Although the response to FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> was modest, it was significantly greater than the response elicited by gp41<sub>607&#x02013;683</sub>. At this dilution, sera from mice that received gp41<sub>607&#x02013;683</sub> alone manifested responses that were no better than sera from mice who received an empty vector control vaccine (<xref ref-type="fig" rid="viruses-10-00100-f006">Figure 6</xref>A).We then wished to determine if the humoral response generated by FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> targeted the C-terminal portion of the MPER or rather residues N-terminal to this region, such as the immunodominant region or the HR2 region [<xref rid="B100-viruses-10-00100" ref-type="bibr">100</xref>]. We therefore coated our ELISA plate with either gp41<sub>607&#x02013;683</sub> as above or a truncated protein devoid of the majority of the MPER (gp41<sub>607&#x02013;671</sub>), then gauged the specificity of pooled sera from our FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> vaccinated group. The response to the protein containing the MPER was at least five-fold greater in magnitude than that to the protein lacking the MPER (<xref ref-type="fig" rid="viruses-10-00100-f006">Figure 6</xref>B), suggesting that immunization with FliC &#x00394;174&#x02013;400 gp41 <sub>607&#x02013;683</sub> did indeed elicit an MPER-specific response. Taken together our results revealed that FliC, deleted of a large portion of its hypervariable region, augmented humoral responses to gp41<sub>607&#x02013;683</sub> and especially the MPER, when gp41<sub>607&#x02013;683</sub> was incorporated into its C-terminus.</p></sec><sec id="sec3dot6-viruses-10-00100"><title>3.6. The Adjuvant Effect of FliC is TLR5 Dependent</title><p>Our DNA vaccine studies revealed that flagellin did indeed impart an adjuvant effect that enhanced immunogenicity of the gp41 antigen. Accordingly, we then wished to gauge the extent to which the adjuvant effect was TLR5 agonist-related or alternatively whether the flagellin scaffold merely acted as a carrier. To do so, we immunized mice with one of three vaccines: pVAX (empty vector control), FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>. In order to minimize any accumulated effect of CD4 helper responses on the humoral response, each group only received a vaccine on days 0 and 14. Blood was collected 2 weeks post the second immunization and analyzed for gp41-specific responses by ELISA. Relative to FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>, an inferior response was observed for mice vaccinated with FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> (<xref ref-type="fig" rid="viruses-10-00100-f007">Figure 7</xref>), indicating that the majority of the adjuvant effect of the FliC scaffold was indeed TLR5 dependent.</p></sec></sec><sec id="sec4-viruses-10-00100"><title>4. Discussion</title><p>The present work demonstrates that codon-optimized <italic>Salmonella</italic> FliC can be expressed in and effectively secreted from mammalian cells. The secreted FliC retains TLR5 agonist activity. These findings are in agreement with previous work where a gene-based or viral vector approach was used to express flagellin [<xref rid="B127-viruses-10-00100" ref-type="bibr">127</xref>,<xref rid="B129-viruses-10-00100" ref-type="bibr">129</xref>,<xref rid="B130-viruses-10-00100" ref-type="bibr">130</xref>,<xref rid="B131-viruses-10-00100" ref-type="bibr">131</xref>].</p><p>Other investigators have selected a variety of sites for insertion of heterologous into flagellin [<xref rid="B23-viruses-10-00100" ref-type="bibr">23</xref>]. This has primarily included either the N or C-terminus [<xref rid="B63-viruses-10-00100" ref-type="bibr">63</xref>,<xref rid="B64-viruses-10-00100" ref-type="bibr">64</xref>,<xref rid="B71-viruses-10-00100" ref-type="bibr">71</xref>,<xref rid="B72-viruses-10-00100" ref-type="bibr">72</xref>,<xref rid="B73-viruses-10-00100" ref-type="bibr">73</xref>,<xref rid="B74-viruses-10-00100" ref-type="bibr">74</xref>,<xref rid="B75-viruses-10-00100" ref-type="bibr">75</xref>,<xref rid="B90-viruses-10-00100" ref-type="bibr">90</xref>] or sites within the hypervariable region [<xref rid="B67-viruses-10-00100" ref-type="bibr">67</xref>,<xref rid="B69-viruses-10-00100" ref-type="bibr">69</xref>] and in some instances both the hypervariable region and C-terminus were used [<xref rid="B62-viruses-10-00100" ref-type="bibr">62</xref>,<xref rid="B68-viruses-10-00100" ref-type="bibr">68</xref>,<xref rid="B79-viruses-10-00100" ref-type="bibr">79</xref>,<xref rid="B84-viruses-10-00100" ref-type="bibr">84</xref>]. Although this selection seems at times to be empiric, these sites have historically been selected to both fully expose the inserted epitopes and avoid disrupting conserved flagellin residues, particularly those amino acids shown to be required for TLR5 agonist activity. </p><p>We postulated that the location of the inserted heterologous sequence, in our case HIV gp41<sub>607&#x02013;683</sub>, would affect the degree of secretion and the TLR5 agonist activity of the resulting fusion protein. Indeed, upon testing we noted tremendous variation for different fusion proteins in regard to these two parameters. While some fusion proteins were highly secreted, their ability to trigger TLR5 mediated signaling was relatively poor. Accordingly, we pursued antigenicity and immunogenicity testing for FliC &#x00394;174&#x02013;400 HIV gp41<sub>607&#x02013;683</sub>, the vaccine candidate that fulfilled both parameters and also lacked immunodominant FliC epitopes [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B45-viruses-10-00100" ref-type="bibr">45</xref>,<xref rid="B46-viruses-10-00100" ref-type="bibr">46</xref>,<xref rid="B47-viruses-10-00100" ref-type="bibr">47</xref>]. We subsequently showed that although FliC &#x00394;174&#x02013;400 HIV gp41<sub>607&#x02013;683</sub> appeared not to be as readily bound by MPER-specific bnAbs, relative to gp41<sub>607&#x02013;683</sub>, it was markedly more immunogenic and appeared to elicit MPER-specific humoral responses. Moreover, we showed that the enhancement of immunogenicity was indeed dependent on TLR5 interaction.</p><p>We did not pursue immunization experiments in TLR5 knock out mice but instead compared humoral responses between mice that received FliC &#x00394;174&#x02013;400 HIV gp41<sub>607&#x02013;683</sub> to those that received FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub>. As expected, immunization with the latter vaccine, which lacked residues essential to TLR5 interaction [<xref rid="B41-viruses-10-00100" ref-type="bibr">41</xref>,<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>], produced a humoral response of relatively low magnitude that was only marginally superior to immunization with an empty vector control vaccine. Although, we have not definitively excluded a contribution of the NAIP/NLRC4 inflammasome [<xref rid="B33-viruses-10-00100" ref-type="bibr">33</xref>] to the adjuvant effect of FliC on humoral responses in the present work, the near complete loss of adjuvant activity with FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> argues against this possibility.</p><p>It could be argued that the adjuvant activity we observed was due in part to binding of our expressed fusion protein to TLR5 on dendritic cells or other APC, resulting in facilitated internalization and antigen processing rather than solely initiation of a pro-inflammatory signaling cascade [<xref rid="B33-viruses-10-00100" ref-type="bibr">33</xref>,<xref rid="B73-viruses-10-00100" ref-type="bibr">73</xref>,<xref rid="B90-viruses-10-00100" ref-type="bibr">90</xref>,<xref rid="B91-viruses-10-00100" ref-type="bibr">91</xref>,<xref rid="B93-viruses-10-00100" ref-type="bibr">93</xref>]. Indeed, we cannot exclude the possibility that TLR5-mediated internalization by APC played some role in adjuvant activity or that antigen internalization, dendritic cell maturation and the induction of a pro-inflammatory milieu occurred contemporaneously.</p><p>Several observations in our present work generate further questions that we believe should be pursued. Two types of post-translational modification were evident in the context of our experiments. First, we discovered that vector-expressed FliC was significantly glycosylated. Indeed, this was predicted by in silico analysis. Moreover, to augment secretion of expressed FliC, all our vectors incorporated a signal peptide fused to the N-terminus of the expressed gene. This design would be expected to guide the protein to the secretory pathway where <italic>N</italic>-glycosylation of FliC might produce progressively oligomeric and branched structures. It is unclear if such glycosylation is advantageous. Whereas future efforts to purify fusion proteins might be complicated by the presence of a broad spectrum of glycoforms, <italic>N</italic>-linked glycosylation of FliC might enhance protein stability or perhaps shield and prevent unmasking of sub-dominant B-cell epitopes and thus allow the humoral response to focus on any inserted heterologous epitopes. Second, vector-expressed FliC which accumulated intracellularly appeared to undergo extensive proteolytic degradation. We did not address the mechanism of degradation in our experiments. Proteasomal or lysosomal degradation may have been induced by over-expression and protein misfolding or aggregation [<xref rid="B132-viruses-10-00100" ref-type="bibr">132</xref>]. It is also interesting to note that the C-terminus of FliC is disordered and appears to be a target of cleavage and subsequent FliC instability [<xref rid="B133-viruses-10-00100" ref-type="bibr">133</xref>]. Specifically addressing these issues might provide strategies to augment secretion of intact FliC and FliC-antigen fusion proteins. Conversely, some propensity for proteolytic cleavage may be advantageous if FliC is taken up by APC and more readily processed for loading onto MHC II.</p><p>A major conclusion of the present work is that the insertion site of a heterologous antigen within the FliC scaffold has a marked impact on the resulting fusion protein&#x02019;s secretion and TLR5 agonist activity. It is conceivable that excessive protein aggregation might modulate these parameters. Alternatively, interference of the inserted antigen with either TLR5 binding or ligand-receptor dimerization, via inter or intramolecular interaction, might hinder robust signaling. Larger inserts might have a more dramatic impact on these parameters. Such considerations might influence the desirability of using flagellin as an epitope scaffold rather than a stand-alone co-delivered adjuvant.</p><p>We did not specifically address to what extent immune humoral responses were also generated towards the FliC scaffold itself. Although the hypervariable region we deleted is known to contain the immunodominant FliC epitopes [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B45-viruses-10-00100" ref-type="bibr">45</xref>,<xref rid="B46-viruses-10-00100" ref-type="bibr">46</xref>,<xref rid="B47-viruses-10-00100" ref-type="bibr">47</xref>], it is possible that its deletion allowed subdominant B-cell epitopes in other regions to elicit a greater response. This may be important to consider with further development, for several reasons. First, dominance of B-cell epitopes within FliC might detract to some extent from a robust humoral response to inserted heterologous epitopes. Second, the generation of antibodies to regions important for TLR5 binding might neutralize FliC&#x02019;s potential to act as an adjuvant [<xref rid="B42-viruses-10-00100" ref-type="bibr">42</xref>,<xref rid="B127-viruses-10-00100" ref-type="bibr">127</xref>]. We must also consider that as FliC and gp41 are delivered together in the context of a fusion protein, FliC CD4 epitopes might provide CD4 T-cell help for antibody responses to gp41. Further assessment of this possibility should be carried out, both to delineate potential helper epitopes and to gauge the need to introduce heterologous helper epitopes to further enhance the humoral response to gp41.</p><p>While we successfully obtained humoral responses to gp41, and to some extent MPER-specificity, the magnitude of responses remained modest. Other investigators have also explored using flagellin as an adjuvant to augment responses to the HIV-1 envelope proteins [<xref rid="B52-viruses-10-00100" ref-type="bibr">52</xref>,<xref rid="B134-viruses-10-00100" ref-type="bibr">134</xref>,<xref rid="B135-viruses-10-00100" ref-type="bibr">135</xref>,<xref rid="B136-viruses-10-00100" ref-type="bibr">136</xref>] but have not explored flagellin&#x02019;s potential to augment responses to gp41 MPER. Prior to expanding our research to include immunization of rabbits or guinea pigs and evaluation of HIV-1 neutralization capacity, we must both address some of the outstanding questions posed above and devise a regimen to further improve immunogenicity. Immunogenicity of our present DNA vaccine, FliC &#x00394;174&#x02013;400 HIV gp41<sub>607&#x02013;683</sub>, would likely be significantly improved by enhanced delivery methods such as in vivo electroporation. A prime-boost strategy will also likely be necessary to achieve the desired level of immunogenicity. Accordingly, DNA prime-protein boost or DNA prime-viral vector boost regimens should be explored.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to Mark A. Wainberg for the unwavering support, keen insight and generous mentorship that he provided throughout the course of our work. This work was supported by the Canadian Institutes of Health Research (CIHR) and the Canadian HIV Vaccine Initiative (CHVI) through an HIV-1/AIDS Vaccine Discovery and Social Research Team Grant (Principal Investigator: Mark A. Wainberg, Co-Investigator: Gerasimos J. Zaharatos; CIHR Funding Reference Number: THA-118628). Luca Melnychuk was a recipient of a Frederick Banting and Charles Best Canada Graduate Scholarship Master&#x02019;s Award from the CIHR (CIHR Funding Reference Number: GSM-129996).</p></ack><app-group><app id="app1-viruses-10-00100"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="http://www.mdpi.com/1999-4915/10/3/100/s1">http://www.mdpi.com/1999-4915/10/3/100/s1</uri>, Supplementary Methods 1: HIV-1 gp41 sequence selection, Supplementary Methods 2: End-point titer selection, Figure S1: In silico prediction of N-glycosylation of FliC amino acid residues, Figure S2: Western blot of cell lysates from transiently transfected 293T before and after treatment with PNGase F.</p><supplementary-material content-type="local-data" id="viruses-10-00100-s001"><media xlink:href="viruses-10-00100-s001.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Lara Ajamian, Luca Melnychuk and Gerasimos J. Zaharatos designed the experiments and analyzed the data. Lara Ajamian, Luca Melnychuk and Patrick Jean-Pierre performed the experiments. Lara Ajamian and Gerasimos J. Zaharatos wrote the manuscript. Gerasimos J. Zaharatos oversaw and guided all experiments. All authors critically reviewed the manuscript and approved the final version.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no conflict of interest to declare.</p></notes><ref-list><title>References</title><ref id="B1-viruses-10-00100"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Vaccines: The fourth century</article-title><source>Clin. Vaccine Immunol.</source><year>2009</year><volume>16</volume><fpage>1709</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1128/CVI.00290-09</pub-id><?supplied-pmid 19793898?><pub-id pub-id-type="pmid">19793898</pub-id></element-citation></ref><ref id="B2-viruses-10-00100"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koff</surname><given-names>W.C.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Johnson</surname><given-names>P.R.</given-names></name><name><surname>Walker</surname><given-names>B.D.</given-names></name><name><surname>King</surname><given-names>C.R.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name><name><surname>Ahmed</surname><given-names>R.</given-names></name><name><surname>Bhan</surname><given-names>M.K.</given-names></name><name><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Accelerating Next-Generation Vaccine Development for Global Disease Prevention</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>1232910</fpage><pub-id pub-id-type="doi">10.1126/science.1232910</pub-id><?supplied-pmid 23723240?><pub-id pub-id-type="pmid">23723240</pub-id></element-citation></ref><ref id="B3-viruses-10-00100"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koff</surname><given-names>W.C.</given-names></name></person-group><article-title>A shot at AIDS</article-title><source>Curr. Opin. Biotechnol.</source><year>2016</year><volume>42</volume><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2016.03.007</pub-id><?supplied-pmid 27153215?><pub-id pub-id-type="pmid">27153215</pub-id></element-citation></ref><ref id="B4-viruses-10-00100"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amed Ouattara</surname><given-names>M.B.L.</given-names></name></person-group><article-title>Vaccines Against Malaria</article-title><source>Clin. Infect. Dis.</source><year>2015</year><volume>60</volume><fpage>930</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu954</pub-id><?supplied-pmid 25452593?><pub-id pub-id-type="pmid">25452593</pub-id></element-citation></ref><ref id="B5-viruses-10-00100"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orme</surname><given-names>I.M.</given-names></name><name><surname>Robinson</surname><given-names>R.T.</given-names></name><name><surname>Cooper</surname><given-names>A.M.</given-names></name></person-group><article-title>The balance between protective and pathogenic immune responses in the TB-infected lung</article-title><source>Nat. Immunol.</source><year>2014</year><volume>16</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/ni.3048</pub-id><?supplied-pmid 25521685?><pub-id pub-id-type="pmid">25521685</pub-id></element-citation></ref><ref id="B6-viruses-10-00100"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K.C.</given-names></name><name><surname>Orme</surname><given-names>I.M.</given-names></name><name><surname>Starke</surname><given-names>J.R.</given-names></name></person-group><article-title>35&#x02014;Tuberculosis vaccines</article-title><source>Vaccines</source><edition>6th ed.</edition><person-group person-group-type="editor"><name><surname>Plotkin</surname><given-names>S.A.</given-names></name><name><surname>Orenstein</surname><given-names>W.A.</given-names></name><name><surname>Offit</surname><given-names>P.A.</given-names></name></person-group><publisher-name>W.B. Saunders</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year><fpage>789</fpage><lpage>811</lpage></element-citation></ref><ref id="B7-viruses-10-00100"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>T.J.</given-names></name></person-group><article-title>Current progress in development of hepatitis C virus vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>869</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1038/nm.3183</pub-id><?supplied-pmid 23836237?><pub-id pub-id-type="pmid">23836237</pub-id></element-citation></ref><ref id="B8-viruses-10-00100"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>P.</given-names></name><name><surname>Kaufmann</surname><given-names>S.H.E.</given-names></name></person-group><article-title>Novel Vaccination Strategies against Tuberculosis</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2014</year><volume>4</volume><fpage>a018523</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a018523</pub-id><?supplied-pmid 24890836?><pub-id pub-id-type="pmid">24890836</pub-id></element-citation></ref><ref id="B9-viruses-10-00100"><label>9.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Parks</surname><given-names>C.L.</given-names></name></person-group><article-title>Replication-Competent Viral Vectors for Vaccine Delivery</article-title><source>Human Vaccines</source><person-group person-group-type="editor"><name><surname>Modjarrad</surname><given-names>K.</given-names></name><name><surname>Koff</surname><given-names>W.C.</given-names></name></person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2017</year><comment>Chapter 2</comment><fpage>25</fpage><lpage>63</lpage></element-citation></ref><ref id="B10-viruses-10-00100"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffman</surname><given-names>R.L.</given-names></name><name><surname>Sher</surname><given-names>A.</given-names></name><name><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine Adjuvants: Putting Innate Immunity to Work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><?supplied-pmid 21029960?><pub-id pub-id-type="pmid">21029960</pub-id></element-citation></ref><ref id="B11-viruses-10-00100"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gar&#x000e7;on</surname><given-names>N.</given-names></name><name><surname>Hem</surname><given-names>S.</given-names></name><name><surname>Friede</surname><given-names>M.</given-names></name></person-group><article-title>Evolution of adjuvants across the centuries</article-title><source>Vaccines</source><edition>6th ed.</edition><publisher-name>Elsevier</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year><fpage>58</fpage><lpage>70</lpage></element-citation></ref><ref id="B12-viruses-10-00100"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levitz</surname><given-names>S.M.</given-names></name><name><surname>Golenbock</surname><given-names>D.T.</given-names></name></person-group><article-title>Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>1284</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.012</pub-id><?supplied-pmid 22424235?><pub-id pub-id-type="pmid">22424235</pub-id></element-citation></ref><ref id="B13-viruses-10-00100"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisonneuve</surname><given-names>C.</given-names></name><name><surname>Bertholet</surname><given-names>S.</given-names></name><name><surname>Philpott</surname><given-names>D.J.</given-names></name><name><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group><article-title>Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>12294</fpage><lpage>12299</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400478111</pub-id><?supplied-pmid 25136133?><pub-id pub-id-type="pmid">25136133</pub-id></element-citation></ref><ref id="B14-viruses-10-00100"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossez</surname><given-names>Y.</given-names></name><name><surname>Wolfson</surname><given-names>E.B.</given-names></name><name><surname>Holmes</surname><given-names>A.</given-names></name><name><surname>Gally</surname><given-names>D.L.</given-names></name><name><surname>Holden</surname><given-names>N.J.</given-names></name></person-group><article-title>Bacterial Flagella: Twist and Stick, or Dodge across the Kingdoms</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004483</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004483</pub-id><?supplied-pmid 25590430?><pub-id pub-id-type="pmid">25590430</pub-id></element-citation></ref><ref id="B15-viruses-10-00100"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>F.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Ozinsky</surname><given-names>A.</given-names></name><name><surname>Hawn</surname><given-names>T.R.</given-names></name><name><surname>Yi</surname><given-names>E.C.</given-names></name><name><surname>Goodlett</surname><given-names>D.R.</given-names></name><name><surname>Eng</surname><given-names>J.K.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Underhill</surname><given-names>D.M.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5: Article: Nature</article-title><source>Nature</source><year>2001</year><volume>410</volume><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/35074106</pub-id><?supplied-pmid 11323673?><pub-id pub-id-type="pmid">11323673</pub-id></element-citation></ref><ref id="B16-viruses-10-00100"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gewirtz</surname><given-names>A.T.</given-names></name><name><surname>Navas</surname><given-names>T.A.</given-names></name><name><surname>Lyons</surname><given-names>S.</given-names></name><name><surname>Godowski</surname><given-names>P.J.</given-names></name><name><surname>Madara</surname><given-names>J.L.</given-names></name></person-group><article-title>Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>1882</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.4.1882</pub-id><?supplied-pmid 11489966?><pub-id pub-id-type="pmid">11489966</pub-id></element-citation></ref><ref id="B17-viruses-10-00100"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Means</surname><given-names>T.K.</given-names></name><name><surname>Hayashi</surname><given-names>F.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name><name><surname>Luster</surname><given-names>A.D.</given-names></name></person-group><article-title>The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells</article-title><source>J. Immunol.</source><year>2003</year><volume>170</volume><fpage>5165</fpage><lpage>5175</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.10.5165</pub-id><?supplied-pmid 12734364?><pub-id pub-id-type="pmid">12734364</pub-id></element-citation></ref><ref id="B18-viruses-10-00100"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E.</given-names></name><name><surname>Hayashi</surname><given-names>F.</given-names></name><name><surname>Strobe</surname><given-names>K.</given-names></name><name><surname>Bergman</surname><given-names>M.A.</given-names></name><name><surname>Barrett</surname><given-names>S.L.R.</given-names></name><name><surname>Cookson</surname><given-names>B.T.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility</article-title><source>Nat. Immunol.</source><year>2003</year><volume>4</volume><fpage>1247</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1038/ni1011</pub-id><?supplied-pmid 14625549?><pub-id pub-id-type="pmid">14625549</pub-id></element-citation></ref><ref id="B19-viruses-10-00100"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murthy</surname><given-names>K.G.K.</given-names></name><name><surname>Deb</surname><given-names>A.</given-names></name><name><surname>Goonesekera</surname><given-names>S.</given-names></name><name><surname>Szab&#x000f3;</surname><given-names>C.</given-names></name><name><surname>Salzman</surname><given-names>A.L.</given-names></name></person-group><article-title>Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>5667</fpage><lpage>5675</lpage><pub-id pub-id-type="doi">10.1074/jbc.M307759200</pub-id><?supplied-pmid 14634022?><pub-id pub-id-type="pmid">14634022</pub-id></element-citation></ref><ref id="B20-viruses-10-00100"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuillet</surname><given-names>V.</given-names></name><name><surname>Medjane</surname><given-names>S.</given-names></name><name><surname>Mondor</surname><given-names>I.</given-names></name><name><surname>Demaria</surname><given-names>O.</given-names></name><name><surname>Pagni</surname><given-names>P.P.</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>J.E.</given-names></name><name><surname>Flavell</surname><given-names>R.A.</given-names></name><name><surname>Alexopoulou</surname><given-names>L.</given-names></name></person-group><article-title>Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria</article-title><source>PNAS</source><year>2006</year><volume>103</volume><fpage>12487</fpage><lpage>12492</lpage><pub-id pub-id-type="doi">10.1073/pnas.0605200103</pub-id><?supplied-pmid 16891416?><pub-id pub-id-type="pmid">16891416</pub-id></element-citation></ref><ref id="B21-viruses-10-00100"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honko</surname><given-names>A.N.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>Effects of flagellin on innate and adaptive immunity</article-title><source>Immunol. Res.</source><year>2005</year><volume>33</volume><fpage>83</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1385/IR:33:1:083</pub-id><pub-id pub-id-type="pmid">16120974</pub-id></element-citation></ref><ref id="B22-viruses-10-00100"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijay-Kumar</surname><given-names>M.</given-names></name><name><surname>Gewirtz</surname><given-names>A.T.</given-names></name></person-group><article-title>Flagellin: Key target of mucosal innate immunity</article-title><source>Mucosal Immunol.</source><year>2009</year><volume>2</volume><fpage>197</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/mi.2009.9</pub-id><?supplied-pmid 19242410?><pub-id pub-id-type="pmid">19242410</pub-id></element-citation></ref><ref id="B23-viruses-10-00100"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizel</surname><given-names>S.B.</given-names></name><name><surname>Bates</surname><given-names>J.T.</given-names></name></person-group><article-title>Flagellin as an adjuvant: Cellular mechanisms and potential</article-title><source>J. Immunol.</source><year>2010</year><volume>185</volume><fpage>5677</fpage><lpage>5682</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002156</pub-id><?supplied-pmid 21048152?><pub-id pub-id-type="pmid">21048152</pub-id></element-citation></ref><ref id="B24-viruses-10-00100"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>S.-I.</given-names></name><name><surname>Kurnasov</surname><given-names>O.</given-names></name><name><surname>Natarajan</surname><given-names>V.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Gudkov</surname><given-names>A.V.</given-names></name><name><surname>Osterman</surname><given-names>A.L.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Structural Basis of TLR5-Flagellin Recognition and Signaling</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>859</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1126/science.1215584</pub-id><?supplied-pmid 22344444?><pub-id pub-id-type="pmid">22344444</pub-id></element-citation></ref><ref id="B25-viruses-10-00100"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>P.D.</given-names></name></person-group><article-title>The Structure of the TLR5-Flagellin Complex: A New Mode of Pathogen Detection, Conserved Receptor Dimerization for Signaling</article-title><source>Sci. Signal.</source><year>2012</year><volume>5</volume><fpage>pe11</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2002963</pub-id><?supplied-pmid 22720339?><pub-id pub-id-type="pmid">22720339</pub-id></element-citation></ref><ref id="B26-viruses-10-00100"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didierlaurent</surname><given-names>A.</given-names></name><name><surname>Ferrero</surname><given-names>I.</given-names></name><name><surname>Otten</surname><given-names>L.A.</given-names></name><name><surname>Dubois</surname><given-names>B.</given-names></name><name><surname>Reinhardt</surname><given-names>M.</given-names></name><name><surname>Carlsen</surname><given-names>H.</given-names></name><name><surname>Blomhoff</surname><given-names>R.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Kraehenbuhl</surname><given-names>J.-P.</given-names></name><name><surname>Sirard</surname><given-names>J.-C.</given-names></name></person-group><article-title>Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>6922</fpage><lpage>6930</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.11.6922</pub-id><?supplied-pmid 15153511?><pub-id pub-id-type="pmid">15153511</pub-id></element-citation></ref><ref id="B27-viruses-10-00100"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lightfield</surname><given-names>K.L.</given-names></name><name><surname>Persson</surname><given-names>J.</given-names></name><name><surname>Brubaker</surname><given-names>S.W.</given-names></name><name><surname>Witte</surname><given-names>C.E.</given-names></name><name><surname>von Moltke</surname><given-names>J.</given-names></name><name><surname>Dunipace</surname><given-names>E.A.</given-names></name><name><surname>Henry</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>Y.-H.</given-names></name><name><surname>Cado</surname><given-names>D.</given-names></name><name><surname>Dietrich</surname><given-names>W.F.</given-names></name><etal/></person-group><article-title>Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1038/ni.1646</pub-id><?supplied-pmid 18724372?><pub-id pub-id-type="pmid">18724372</pub-id></element-citation></ref><ref id="B28-viruses-10-00100"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofoed</surname><given-names>E.M.</given-names></name><name><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>592</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/nature10394</pub-id><?supplied-pmid 21874021?><pub-id pub-id-type="pmid">21874021</pub-id></element-citation></ref><ref id="B29-viruses-10-00100"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortmann</surname><given-names>J.</given-names></name><name><surname>Brubaker</surname><given-names>S.W.</given-names></name><name><surname>Monack</surname><given-names>D.M.</given-names></name></person-group><article-title>Cutting Edge: Inflammasome Activation in Primary Human Macrophages Is Dependent on Flagellin</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>815</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1403100</pub-id><?supplied-pmid 26109648?><pub-id pub-id-type="pmid">26109648</pub-id></element-citation></ref><ref id="B30-viruses-10-00100"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>I.</given-names></name><name><surname>Tenthorey</surname><given-names>J.L.</given-names></name><name><surname>Nichols</surname><given-names>R.D.</given-names></name><name><surname>Moussawi Al</surname><given-names>K.</given-names></name><name><surname>Kang</surname><given-names>J.J.</given-names></name><name><surname>Kang</surname><given-names>C.</given-names></name><name><surname>Kazmierczak</surname><given-names>B.I.</given-names></name><name><surname>Vance</surname><given-names>R.E.</given-names></name></person-group><article-title>NAIP proteins are required for cytosolic detection of specific bacterial ligands in vivo</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>657</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1084/jem.20151809</pub-id><?supplied-pmid 27045008?><pub-id pub-id-type="pmid">27045008</pub-id></element-citation></ref><ref id="B31-viruses-10-00100"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Shao</surname><given-names>F.</given-names></name></person-group><article-title>Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in mice</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1084/jem.20160006</pub-id><?supplied-pmid 27114610?><pub-id pub-id-type="pmid">27114610</pub-id></element-citation></ref><ref id="B32-viruses-10-00100"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>F.</given-names></name></person-group><article-title>The NAIP&#x02013;NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus</article-title><source>Immunol. Rev.</source><year>2015</year><volume>265</volume><fpage>85</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1111/imr.12293</pub-id><?supplied-pmid 25879286?><pub-id pub-id-type="pmid">25879286</pub-id></element-citation></ref><ref id="B33-viruses-10-00100"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijay-Kumar</surname><given-names>M.</given-names></name><name><surname>Carvalho</surname><given-names>F.A.</given-names></name><name><surname>Aitken</surname><given-names>J.D.</given-names></name><name><surname>Fifadara</surname><given-names>N.H.</given-names></name><name><surname>Gewirtz</surname><given-names>A.T.</given-names></name></person-group><article-title>TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin</article-title><source>Eur. J. Immunol.</source><year>2010</year><volume>40</volume><fpage>3528</fpage><lpage>3534</lpage><pub-id pub-id-type="doi">10.1002/eji.201040421</pub-id><?supplied-pmid 21072873?><pub-id pub-id-type="pmid">21072873</pub-id></element-citation></ref><ref id="B34-viruses-10-00100"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>E.A.</given-names></name><name><surname>Alpuche-Aranda</surname><given-names>C.M.</given-names></name><name><surname>Dors</surname><given-names>M.</given-names></name><name><surname>Clark</surname><given-names>A.E.</given-names></name><name><surname>Bader</surname><given-names>M.W.</given-names></name><name><surname>Miller</surname><given-names>S.I.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1&#x003b2; via Ipaf</article-title><source>Nat. Immunol.</source><year>2006</year><volume>7</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1038/ni1344</pub-id><?supplied-pmid 16648853?><pub-id pub-id-type="pmid">16648853</pub-id></element-citation></ref><ref id="B35-viruses-10-00100"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchi</surname><given-names>L.</given-names></name><name><surname>Amer</surname><given-names>A.</given-names></name><name><surname>Body-Malapel</surname><given-names>M.</given-names></name><name><surname>Kanneganti</surname><given-names>T.-D.</given-names></name><name><surname>&#x000d6;z&#x000f6;ren</surname><given-names>N.</given-names></name><name><surname>Jagirdar</surname><given-names>R.</given-names></name><name><surname>Inohara</surname><given-names>N.</given-names></name><name><surname>Vandenabeele</surname><given-names>P.</given-names></name><name><surname>Bertin</surname><given-names>J.</given-names></name><name><surname>Coyle</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1&#x003b2; in salmonella-infected macrophages</article-title><source>Nat. Immunol.</source><year>2006</year><volume>7</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1038/ni1346</pub-id><?supplied-pmid 16648852?><pub-id pub-id-type="pmid">16648852</pub-id></element-citation></ref><ref id="B36-viruses-10-00100"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchi</surname><given-names>L.</given-names></name><name><surname>Eigenbrod</surname><given-names>T.</given-names></name><name><surname>Mu&#x000f1;oz-Planillo</surname><given-names>R.</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>G.</given-names></name></person-group><article-title>The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesis</article-title><source>Nat. Immunol.</source><year>2009</year><volume>10</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/ni.1703</pub-id><?supplied-pmid 19221555?><pub-id pub-id-type="pmid">19221555</pub-id></element-citation></ref><ref id="B37-viruses-10-00100"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aachoui</surname><given-names>Y.</given-names></name><name><surname>Miao</surname><given-names>E.A.</given-names></name></person-group><article-title>Down with doublespeak: NAIP/NLRC4 inflammasomes get specific</article-title><source>J. Exp. Med.</source><year>2016</year><volume>213</volume><fpage>646</fpage><pub-id pub-id-type="doi">10.1084/jem.2135insight1</pub-id><?supplied-pmid 27140198?><pub-id pub-id-type="pmid">27140198</pub-id></element-citation></ref><ref id="B38-viruses-10-00100"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonekura</surname><given-names>K.</given-names></name><name><surname>Maki-Yonekura</surname><given-names>S.</given-names></name><name><surname>Namba</surname><given-names>K.</given-names></name></person-group><article-title>Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy</article-title><source>Nature</source><year>2003</year><volume>424</volume><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/nature01830</pub-id><?supplied-pmid 12904785?><pub-id pub-id-type="pmid">12904785</pub-id></element-citation></ref><ref id="B39-viruses-10-00100"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatson</surname><given-names>S.A.</given-names></name><name><surname>Minamino</surname><given-names>T.</given-names></name><name><surname>Pallen</surname><given-names>M.J.</given-names></name></person-group><article-title>Variation in bacterial flagellins: From sequence to structure</article-title><source>Trends Microbiol.</source><year>2006</year><volume>14</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2006.02.008</pub-id><?supplied-pmid 16540320?><pub-id pub-id-type="pmid">16540320</pub-id></element-citation></ref><ref id="B40-viruses-10-00100"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eaves-Pyles</surname><given-names>T.D.</given-names></name><name><surname>Wong</surname><given-names>H.R.</given-names></name><name><surname>Odoms</surname><given-names>K.</given-names></name><name><surname>Pyles</surname><given-names>R.B.</given-names></name></person-group><article-title>Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>7009</fpage><lpage>7016</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.12.7009</pub-id><?supplied-pmid 11739521?><pub-id pub-id-type="pmid">11739521</pub-id></element-citation></ref><ref id="B41-viruses-10-00100"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen-Nissen</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Strobe</surname><given-names>K.L.</given-names></name><name><surname>Barrett</surname><given-names>S.L.R.</given-names></name><name><surname>Cookson</surname><given-names>B.T.</given-names></name><name><surname>Logan</surname><given-names>S.M.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>Evasion of Toll-like receptor 5 by flagellated bacteria</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>9247</fpage><lpage>9252</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502040102</pub-id><?supplied-pmid 15956202?><pub-id pub-id-type="pmid">15956202</pub-id></element-citation></ref><ref id="B42-viruses-10-00100"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nempont</surname><given-names>C.</given-names></name><name><surname>Cayet</surname><given-names>D.</given-names></name><name><surname>Rumbo</surname><given-names>M.</given-names></name><name><surname>Bompard</surname><given-names>C.</given-names></name><name><surname>Villeret</surname><given-names>V.</given-names></name><name><surname>Sirard</surname><given-names>J.-C.</given-names></name></person-group><article-title>Deletion of flagellin&#x02019;s hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>2036</fpage><lpage>2043</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.3.2036</pub-id><?supplied-pmid 18641341?><pub-id pub-id-type="pmid">18641341</pub-id></element-citation></ref><ref id="B43-viruses-10-00100"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W.S.</given-names></name><name><surname>Jeon</surname><given-names>Y.J.</given-names></name><name><surname>Namgung</surname><given-names>B.</given-names></name><name><surname>Hong</surname><given-names>M.</given-names></name><name><surname>Yoon</surname><given-names>S.-I.</given-names></name></person-group><article-title>A conserved TLR5 binding and activation hot spot on flagellin</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>40878</fpage><pub-id pub-id-type="doi">10.1038/srep40878</pub-id><?supplied-pmid 28106112?><pub-id pub-id-type="pmid">28106112</pub-id></element-citation></ref><ref id="B44-viruses-10-00100"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halff</surname><given-names>E.F.</given-names></name><name><surname>Diebolder</surname><given-names>C.A.</given-names></name><name><surname>Versteeg</surname><given-names>M.</given-names></name><name><surname>Schouten</surname><given-names>A.</given-names></name><name><surname>Brondijk</surname><given-names>T.H.C.</given-names></name><name><surname>Huizinga</surname><given-names>E.G.</given-names></name></person-group><article-title>Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N- and C-terminal regions of flagellin</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>38460</fpage><lpage>38472</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.393512</pub-id><?supplied-pmid 23012363?><pub-id pub-id-type="pmid">23012363</pub-id></element-citation></ref><ref id="B45-viruses-10-00100"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwajima</surname><given-names>G.</given-names></name></person-group><article-title>Flagellin domain that affects H antigenicity of Escherichia coli K-12</article-title><source>J. Bacteriol.</source><year>1988</year><volume>170</volume><fpage>485</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1128/jb.170.1.485-488.1988</pub-id><?supplied-pmid 3275631?><pub-id pub-id-type="pmid">3275631</pub-id></element-citation></ref><ref id="B46-viruses-10-00100"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K.</given-names></name><name><surname>Aizawa</surname><given-names>S.</given-names></name><name><surname>Yamaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Flagellar filament structure and cell motility of Salmonella typhimurium mutants lacking part of the outer domain of flagellin</article-title><source>J. Bacteriol.</source><year>1995</year><volume>177</volume><fpage>1090</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1128/jb.177.4.1090-1093.1995</pub-id><?supplied-pmid 7860589?><pub-id pub-id-type="pmid">7860589</pub-id></element-citation></ref><ref id="B47-viruses-10-00100"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.S.</given-names></name><name><surname>Rivkina</surname><given-names>M.</given-names></name><name><surname>Stocker</surname><given-names>B.A.</given-names></name><name><surname>Robinson</surname><given-names>W.S.</given-names></name></person-group><article-title>Hypervariable region IV of Salmonella gene fliCd encodes a dominant surface epitope and a stabilizing factor for functional flagella</article-title><source>J. Bacteriol.</source><year>1994</year><volume>176</volume><fpage>2406</fpage><lpage>2414</lpage><pub-id pub-id-type="doi">10.1128/jb.176.8.2406-2414.1994</pub-id><?supplied-pmid 7512552?><pub-id pub-id-type="pmid">7512552</pub-id></element-citation></ref><ref id="B48-viruses-10-00100"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoiseth</surname><given-names>S.K.</given-names></name><name><surname>Stocker</surname><given-names>B.A.D.</given-names></name></person-group><article-title>Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines</article-title><source>Nature</source><year>1981</year><volume>291</volume><fpage>238</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/291238a0</pub-id><?supplied-pmid 7015147?><pub-id pub-id-type="pmid">7015147</pub-id></element-citation></ref><ref id="B49-viruses-10-00100"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>A.</given-names></name><name><surname>Hormaeche</surname><given-names>C.E.</given-names></name><name><surname>de Hormaeche</surname><given-names>R.D.</given-names></name><name><surname>Winther</surname><given-names>M.</given-names></name><name><surname>Dougan</surname><given-names>G.</given-names></name><name><surname>Maskell</surname><given-names>D.J.</given-names></name><name><surname>Stocker</surname><given-names>B.A.D.</given-names></name></person-group><article-title>An Attenuated aroA Salmonella typhimurium Vaccine Elicits Humoral and Cellular Immunity to Cloned &#x003b2;-Galactosidase in Mice</article-title><source>J. Infect. Dis.</source><year>1987</year><volume>155</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/infdis/155.1.86</pub-id><?supplied-pmid 3098864?><pub-id pub-id-type="pmid">3098864</pub-id></element-citation></ref><ref id="B50-viruses-10-00100"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadoff</surname><given-names>J.C.</given-names></name><name><surname>Ballou</surname><given-names>W.R.</given-names></name><name><surname>Baron</surname><given-names>L.S.</given-names></name><name><surname>Majarian</surname><given-names>W.R.</given-names></name><name><surname>Brey</surname><given-names>R.N.</given-names></name><name><surname>Hockmeyer</surname><given-names>W.T.</given-names></name><name><surname>Young</surname><given-names>J.F.</given-names></name><name><surname>Cryz</surname><given-names>S.J.</given-names></name><name><surname>Ou</surname><given-names>J.</given-names></name><name><surname>Lowell</surname><given-names>G.H.</given-names></name><etal/></person-group><article-title>Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria</article-title><source>Science</source><year>1988</year><volume>240</volume><fpage>336</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1126/science.3281260</pub-id><?supplied-pmid 3281260?><pub-id pub-id-type="pmid">3281260</pub-id></element-citation></ref><ref id="B51-viruses-10-00100"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatfield</surname><given-names>S.</given-names></name><name><surname>Strugnell</surname><given-names>R.</given-names></name><name><surname>Dougan</surname><given-names>G.</given-names></name></person-group><article-title>Live Salmonella as vaccines and carriers of foreign antigenic determinants</article-title><source>Vaccine</source><year>1989</year><volume>7</volume><fpage>495</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(89)90271-5</pub-id><pub-id pub-id-type="pmid">2481908</pub-id></element-citation></ref><ref id="B52-viruses-10-00100"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>S.M.</given-names></name><name><surname>Jacob</surname><given-names>C.O.</given-names></name><name><surname>Stocker</surname><given-names>B.A.</given-names></name></person-group><article-title>Immune response to cholera toxin epitope inserted in Salmonella flagellin</article-title><source>Science</source><year>1989</year><volume>244</volume><fpage>70</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1126/science.2468182</pub-id><?supplied-pmid 2468182?><pub-id pub-id-type="pmid">2468182</pub-id></element-citation></ref><ref id="B53-viruses-10-00100"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J.Y.</given-names></name><name><surname>Newton</surname><given-names>S.</given-names></name><name><surname>Judd</surname><given-names>A.</given-names></name><name><surname>Stocker</surname><given-names>B.</given-names></name><name><surname>Robinson</surname><given-names>W.S.</given-names></name></person-group><article-title>Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1989</year><volume>86</volume><fpage>4726</fpage><lpage>4730</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.12.4726</pub-id><?supplied-pmid 2471978?><pub-id pub-id-type="pmid">2471978</pub-id></element-citation></ref><ref id="B54-viruses-10-00100"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>S.M.</given-names></name><name><surname>Kotb</surname><given-names>M.</given-names></name><name><surname>Poirier</surname><given-names>T.P.</given-names></name><name><surname>Stocker</surname><given-names>B.A.</given-names></name><name><surname>Beachey</surname><given-names>E.H.</given-names></name></person-group><article-title>Expression and immunogenicity of a streptococcal M protein epitope inserted in Salmonella flagellin</article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>2158</fpage><lpage>2165</lpage><?supplied-pmid 2037377?><pub-id pub-id-type="pmid">2037377</pub-id></element-citation></ref><ref id="B55-viruses-10-00100"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>C&#x000e1;rdenas</surname><given-names>L.</given-names></name><name><surname>Clements</surname><given-names>J.D.</given-names></name></person-group><article-title>Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens</article-title><source>Clin. Microbiol. Rev.</source><year>1992</year><volume>5</volume><fpage>328</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1128/CMR.5.3.328</pub-id><?supplied-pmid 1498769?><pub-id pub-id-type="pmid">1498769</pub-id></element-citation></ref><ref id="B56-viruses-10-00100"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McEwen</surname><given-names>J.</given-names></name><name><surname>Levi</surname><given-names>R.</given-names></name><name><surname>Horwitz</surname><given-names>R.J.</given-names></name><name><surname>Arnon</surname><given-names>R.</given-names></name></person-group><article-title>Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice</article-title><source>Vaccine</source><year>1992</year><volume>10</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(92)90071-Q</pub-id><pub-id pub-id-type="pmid">1376012</pub-id></element-citation></ref><ref id="B57-viruses-10-00100"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>N.</given-names></name></person-group><article-title>Induction of a cellular immune response to a defined T-cell epitope as an insert in the flagellin of a live vaccine strain of Salmonella</article-title><source>Vaccine</source><year>1995</year><volume>13</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)93308-V</pub-id><pub-id pub-id-type="pmid">7543230</pub-id></element-citation></ref><ref id="B58-viruses-10-00100"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>R.</given-names></name></person-group><article-title>Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00088-I</pub-id><pub-id pub-id-type="pmid">8821654</pub-id></element-citation></ref><ref id="B59-viruses-10-00100"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Yedidia</surname><given-names>T.</given-names></name><name><surname>Arnon</surname><given-names>R.</given-names></name></person-group><article-title>Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine</article-title><source>Immunol. Lett.</source><year>1998</year><volume>64</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0165-2478(98)00073-X</pub-id><pub-id pub-id-type="pmid">9865596</pub-id></element-citation></ref><ref id="B60-viruses-10-00100"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Yedidia</surname><given-names>T.</given-names></name><name><surname>Tarrab-Hazdai</surname><given-names>R.</given-names></name><name><surname>Schechtman</surname><given-names>D.</given-names></name><name><surname>Arnon</surname><given-names>R.</given-names></name></person-group><article-title>Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni</article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>4360</fpage><lpage>4366</lpage><?supplied-pmid 10456875?><pub-id pub-id-type="pmid">10456875</pub-id></element-citation></ref><ref id="B61-viruses-10-00100"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocker</surname><given-names>B.A.D.</given-names></name><name><surname>Newton</surname><given-names>S.M.C.</given-names></name></person-group><article-title>Immune Responses to Epitopes Inserted in Salmonella Flagellin</article-title><source>Int. Rev. Immunol.</source><year>2009</year><volume>11</volume><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.3109/08830189409061724</pub-id></element-citation></ref><ref id="B62-viruses-10-00100"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Tarbet</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Reiserova</surname><given-names>L.</given-names></name><name><surname>Weaver</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Hou</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Parent</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Immunogenicity and Efficacy of Flagellin-Fused Vaccine Candidates Targeting 2009 Pandemic H1N1 Influenza in Mice</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e20928</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020928</pub-id><?supplied-pmid 21687743?><pub-id pub-id-type="pmid">21687743</pub-id></element-citation></ref><ref id="B63-viruses-10-00100"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghose</surname><given-names>C.</given-names></name><name><surname>Verhagen</surname><given-names>J.M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Chenesseau</surname><given-names>O.</given-names></name><name><surname>Kelly</surname><given-names>C.P.</given-names></name><name><surname>Ho</surname><given-names>D.D.</given-names></name></person-group><article-title>Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease</article-title><source>Infect. Immun.</source><year>2013</year><volume>81</volume><fpage>2190</fpage><lpage>2196</lpage><?supplied-pmid 23545305?><pub-id pub-id-type="pmid">23545305</pub-id></element-citation></ref><ref id="B64-viruses-10-00100"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carapau</surname><given-names>D.</given-names></name><name><surname>Mitchell</surname><given-names>R.</given-names></name><name><surname>Nacer</surname><given-names>A.</given-names></name><name><surname>Shaw</surname><given-names>A.</given-names></name><name><surname>Othoro</surname><given-names>C.</given-names></name><name><surname>Frevert</surname><given-names>U.</given-names></name><name><surname>Nardin</surname><given-names>E.</given-names></name></person-group><article-title>Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin</article-title><source>Infect. Immun.</source><year>2013</year><volume>81</volume><fpage>4350</fpage><lpage>4362</lpage><pub-id pub-id-type="doi">10.1128/IAI.00263-13</pub-id><?supplied-pmid 24042110?><pub-id pub-id-type="pmid">24042110</pub-id></element-citation></ref><ref id="B65-viruses-10-00100"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>M.T.A.</given-names></name><name><surname>Camacho</surname><given-names>A.G.A.</given-names></name><name><surname>Teixeira</surname><given-names>L.H.</given-names></name><name><surname>Bargieri</surname><given-names>D.Y.</given-names></name><name><surname>Soares</surname><given-names>I.S.</given-names></name><name><surname>Tararam</surname><given-names>C.A.</given-names></name><name><surname>Rodrigues</surname><given-names>M.M.</given-names></name></person-group><article-title>Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>1418</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1128/CVI.00312-13</pub-id><?supplied-pmid 23863502?><pub-id pub-id-type="pmid">23863502</pub-id></element-citation></ref><ref id="B66-viruses-10-00100"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Reiserova</surname><given-names>L.</given-names></name><name><surname>Trivedi</surname><given-names>U.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Noah</surname><given-names>D.</given-names></name><name><surname>Hou</surname><given-names>F.</given-names></name><name><surname>Weaver</surname><given-names>B.</given-names></name><name><surname>Tussey</surname><given-names>L.</given-names></name></person-group><article-title>Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>6833</fpage><lpage>6838</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.013</pub-id><?supplied-pmid 23000130?><pub-id pub-id-type="pmid">23000130</pub-id></element-citation></ref><ref id="B67-viruses-10-00100"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braga</surname><given-names>C.J.M.</given-names></name><name><surname>Massis</surname><given-names>L.M.</given-names></name><name><surname>Sbrogio-Almeida</surname><given-names>M.E.</given-names></name><name><surname>Alencar</surname><given-names>B.C.G.</given-names></name><name><surname>Bargieri</surname><given-names>D.Y.</given-names></name><name><surname>Boscardin</surname><given-names>S.B.</given-names></name><name><surname>Rodrigues</surname><given-names>M.M.</given-names></name><name><surname>Ferreira</surname><given-names>L.C.S.</given-names></name></person-group><article-title>CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>1373</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.11.003</pub-id><?supplied-pmid 19932669?><pub-id pub-id-type="pmid">19932669</pub-id></element-citation></ref><ref id="B68-viruses-10-00100"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yun</surname><given-names>N.E.</given-names></name><name><surname>Poussard</surname><given-names>A.L.</given-names></name><name><surname>Smith</surname><given-names>J.N.</given-names></name><name><surname>Smith</surname><given-names>J.K.</given-names></name><name><surname>Borisevich</surname><given-names>V.</given-names></name><name><surname>Linde</surname><given-names>J.J.</given-names></name><name><surname>Zacks</surname><given-names>M.A.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5875</fpage><lpage>5884</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.060</pub-id><?supplied-pmid 19654064?><pub-id pub-id-type="pmid">19654064</pub-id></element-citation></ref><ref id="B69-viruses-10-00100"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizel</surname><given-names>S.B.</given-names></name><name><surname>Graff</surname><given-names>A.H.</given-names></name><name><surname>Sriranganathan</surname><given-names>N.</given-names></name><name><surname>Ervin</surname><given-names>S.</given-names></name><name><surname>Lees</surname><given-names>C.J.</given-names></name><name><surname>Lively</surname><given-names>M.O.</given-names></name><name><surname>Hantgan</surname><given-names>R.R.</given-names></name><name><surname>Thomas</surname><given-names>M.J.</given-names></name><name><surname>Wood</surname><given-names>J.</given-names></name><name><surname>Bell</surname><given-names>B.</given-names></name></person-group><article-title>Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates</article-title><source>Clin. Vaccine Immunol.</source><year>2009</year><volume>16</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1128/CVI.00333-08</pub-id><?supplied-pmid 18987167?><pub-id pub-id-type="pmid">18987167</pub-id></element-citation></ref><ref id="B70-viruses-10-00100"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>K.N.</given-names></name><name><surname>Phipps</surname><given-names>J.P.</given-names></name><name><surname>Johnson</surname><given-names>J.B.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>A Recombinant Flagellin-Poxvirus Fusion Protein Vaccine Elicits Complement-Dependent Protection Against Respiratory Challenge with Vaccinia Virus in Mice</article-title><source>Viral Immunol.</source><year>2010</year><volume>23</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1089/vim.2009.0107</pub-id><?supplied-pmid 20374000?><pub-id pub-id-type="pmid">20374000</pub-id></element-citation></ref><ref id="B71-viruses-10-00100"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huleatt</surname><given-names>J.W.</given-names></name><name><surname>Nakaar</surname><given-names>V.</given-names></name><name><surname>Desai</surname><given-names>P.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Hewitt</surname><given-names>D.</given-names></name><name><surname>Jacobs</surname><given-names>A.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>McDonald</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Evans</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>201</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.10.062</pub-id><?supplied-pmid 18063235?><pub-id pub-id-type="pmid">18063235</pub-id></element-citation></ref><ref id="B72-viruses-10-00100"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>W.F.</given-names></name><name><surname>Huleatt</surname><given-names>J.W.</given-names></name><name><surname>Foellmer</surname><given-names>H.G.</given-names></name><name><surname>Hewitt</surname><given-names>D.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Desai</surname><given-names>P.</given-names></name><name><surname>Price</surname><given-names>A.</given-names></name><name><surname>Jacobs</surname><given-names>A.</given-names></name><name><surname>Takahashi</surname><given-names>V.N.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity</article-title><source>J. Infect. Dis.</source><year>2007</year><volume>195</volume><fpage>1607</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1086/517613</pub-id><?supplied-pmid 17471430?><pub-id pub-id-type="pmid">17471430</pub-id></element-citation></ref><ref id="B73-viruses-10-00100"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huleatt</surname><given-names>J.W.</given-names></name><name><surname>Jacobs</surname><given-names>A.R.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Desai</surname><given-names>P.</given-names></name><name><surname>Kopp</surname><given-names>E.B.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Nakaar</surname><given-names>V.</given-names></name><name><surname>Powell</surname><given-names>T.J.</given-names></name></person-group><article-title>Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>763</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.08.013</pub-id><?supplied-pmid 16968658?><pub-id pub-id-type="pmid">16968658</pub-id></element-citation></ref><ref id="B74-viruses-10-00100"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>M.</given-names></name><name><surname>Kang</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Z.</given-names></name><name><surname>Jiao</surname><given-names>X.</given-names></name></person-group><article-title>Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0150678</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0150678</pub-id><?supplied-pmid 26930068?><pub-id pub-id-type="pmid">26930068</pub-id></element-citation></ref><ref id="B75-viruses-10-00100"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepanova</surname><given-names>L.A.</given-names></name><name><surname>Kotlyarov</surname><given-names>R.Y.</given-names></name><name><surname>Kovaleva</surname><given-names>A.A.</given-names></name><name><surname>Potapchuk</surname><given-names>M.V.</given-names></name><name><surname>Korotkov</surname><given-names>A.V.</given-names></name><name><surname>Sergeeva</surname><given-names>M.V.</given-names></name><name><surname>Kasianenko</surname><given-names>M.A.</given-names></name><name><surname>Kuprianov</surname><given-names>V.V.</given-names></name><name><surname>Ravin</surname><given-names>N.V.</given-names></name><name><surname>Tsybalova</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Protection against Multiple Influenza A Virus Strains Induced by Candidate Recombinant Vaccine Based on Heterologous M2e Peptides Linked to Flagellin</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0119520</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0119520</pub-id><?supplied-pmid 25799221?><pub-id pub-id-type="pmid">25799221</pub-id></element-citation></ref><ref id="B76-viruses-10-00100"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalnin</surname><given-names>K.</given-names></name><name><surname>Tibbitts</surname><given-names>T.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Stegalkina</surname><given-names>S.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Costa</surname><given-names>V.</given-names></name><name><surname>Sabharwal</surname><given-names>R.</given-names></name><name><surname>Anderson</surname><given-names>S.F.</given-names></name><name><surname>Day</surname><given-names>P.M.</given-names></name><name><surname>Christensen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>3540</fpage><lpage>3547</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.04.032</pub-id><?supplied-pmid 24780250?><pub-id pub-id-type="pmid">24780250</pub-id></element-citation></ref><ref id="B77-viruses-10-00100"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.-Z.</given-names></name><name><surname>Gill</surname><given-names>H.S.</given-names></name><name><surname>Kang</surname><given-names>S.-M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.-C.</given-names></name><name><surname>Vassilieva</surname><given-names>E.V.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand</article-title><source>Clin. Vaccine Immunol.</source><year>2012</year><volume>19</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1128/CVI.00153-12</pub-id><?supplied-pmid 22647270?><pub-id pub-id-type="pmid">22647270</pub-id></element-citation></ref><ref id="B78-viruses-10-00100"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.-Z.</given-names></name><name><surname>Quan</surname><given-names>F.-S.</given-names></name><name><surname>Kang</surname><given-names>S.-M.</given-names></name><name><surname>Bozja</surname><given-names>J.</given-names></name><name><surname>Skountzou</surname><given-names>I.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>11813</fpage><lpage>11823</lpage><pub-id pub-id-type="doi">10.1128/JVI.01076-08</pub-id><?supplied-pmid 18786995?><pub-id pub-id-type="pmid">18786995</pub-id></element-citation></ref><ref id="B79-viruses-10-00100"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Beasley</surname><given-names>D.W.C.</given-names></name><name><surname>Putnak</surname><given-names>R.</given-names></name><name><surname>Parent</surname><given-names>J.</given-names></name><name><surname>Misczak</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Reiserova</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and Monkeys</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>22</volume><fpage>516</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1128/CVI.00770-14</pub-id><?supplied-pmid 25761459?><pub-id pub-id-type="pmid">25761459</pub-id></element-citation></ref><ref id="B80-viruses-10-00100"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>K.-H.</given-names></name><name><surname>Chang</surname><given-names>L.-S.</given-names></name><name><surname>Tian</surname><given-names>C.-Y.</given-names></name><name><surname>Yeh</surname><given-names>Y.-C.</given-names></name><name><surname>Chen</surname><given-names>Y.-J.</given-names></name><name><surname>Chuang</surname><given-names>T.-H.</given-names></name><name><surname>Liu</surname><given-names>S.-J.</given-names></name><name><surname>Leng</surname><given-names>C.-H.</given-names></name></person-group><article-title>Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>24199</fpage><pub-id pub-id-type="doi">10.1038/srep24199</pub-id><?supplied-pmid 27063435?><pub-id pub-id-type="pmid">27063435</pub-id></element-citation></ref><ref id="B81-viruses-10-00100"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>H.K.</given-names></name><name><surname>Rock</surname><given-names>M.T.</given-names></name><name><surname>Johnson</surname><given-names>C.</given-names></name><name><surname>Tussey</surname><given-names>L.</given-names></name><name><surname>Kavita</surname><given-names>U.</given-names></name><name><surname>Shanker</surname><given-names>A.</given-names></name><name><surname>Shaw</surname><given-names>A.R.</given-names></name><name><surname>Taylor</surname><given-names>D.N.</given-names></name></person-group><article-title>Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e14442</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0014442</pub-id><?supplied-pmid 21203437?><pub-id pub-id-type="pmid">21203437</pub-id></element-citation></ref><ref id="B82-viruses-10-00100"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treanor</surname><given-names>J.J.</given-names></name><name><surname>Taylor</surname><given-names>D.N.</given-names></name><name><surname>Tussey</surname><given-names>L.</given-names></name><name><surname>Hay</surname><given-names>C.</given-names></name><name><surname>Nolan</surname><given-names>C.</given-names></name><name><surname>Fitzgerald</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Kavita</surname><given-names>U.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Dark</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant hemagglutinin influenza&#x02013;flagellin fusion vaccine (VAX125) in healthy young adults</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>8268</fpage><lpage>8274</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.10.009</pub-id><?supplied-pmid 20969925?><pub-id pub-id-type="pmid">20969925</pub-id></element-citation></ref><ref id="B83-viruses-10-00100"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turley</surname><given-names>C.B.</given-names></name><name><surname>Rupp</surname><given-names>R.E.</given-names></name><name><surname>Johnson</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>D.N.</given-names></name><name><surname>Wolfson</surname><given-names>J.</given-names></name><name><surname>Tussey</surname><given-names>L.</given-names></name><name><surname>Kavita</surname><given-names>U.</given-names></name><name><surname>Stanberry</surname><given-names>L.</given-names></name><name><surname>Shaw</surname><given-names>A.</given-names></name></person-group><article-title>Safety and immunogenicity of a recombinant M2e&#x02013;flagellin influenza vaccine (STF2.4xM2e) in healthy adults</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>5145</fpage><lpage>5152</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.05.041</pub-id><?supplied-pmid 21624416?><pub-id pub-id-type="pmid">21624416</pub-id></element-citation></ref><ref id="B84-viruses-10-00100"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>D.N.</given-names></name><name><surname>Treanor</surname><given-names>J.J.</given-names></name><name><surname>Sheldon</surname><given-names>E.A.</given-names></name><name><surname>Johnson</surname><given-names>C.</given-names></name><name><surname>Umlauf</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Kavita</surname><given-names>U.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Tussey</surname><given-names>L.</given-names></name><name><surname>Ozer</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5761</fpage><lpage>5769</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.086</pub-id><?supplied-pmid 22796139?><pub-id pub-id-type="pmid">22796139</pub-id></element-citation></ref><ref id="B85-viruses-10-00100"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tussey</surname><given-names>L.</given-names></name><name><surname>Strout</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>M.</given-names></name><name><surname>Johnson</surname><given-names>C.</given-names></name><name><surname>Lucksinger</surname><given-names>G.</given-names></name><name><surname>Umlauf</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Abraham</surname><given-names>K.</given-names></name><name><surname>White</surname><given-names>C.J.</given-names></name></person-group><article-title>Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins</article-title><source>Open Forum Infect. Dis.</source><year>2016</year><volume>3</volume><fpage>ofw015</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofw015</pub-id><?supplied-pmid 26925433?><pub-id pub-id-type="pmid">26925433</pub-id></element-citation></ref><ref id="B86-viruses-10-00100"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McSorley</surname><given-names>S.J.</given-names></name><name><surname>Ehst</surname><given-names>B.D.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Gewirtz</surname><given-names>A.T.</given-names></name></person-group><article-title>Bacterial Flagellin Is an Effective Adjuvant for CD4+ T Cells In Vivo</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>3914</fpage><lpage>3919</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.7.3914</pub-id><?supplied-pmid 12244190?><pub-id pub-id-type="pmid">12244190</pub-id></element-citation></ref><ref id="B87-viruses-10-00100"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honko</surname><given-names>A.N.</given-names></name><name><surname>Sriranganathan</surname><given-names>N.</given-names></name><name><surname>Lees</surname><given-names>C.J.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>1113</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1128/IAI.74.2.1113-1120.2006</pub-id><?supplied-pmid 16428759?><pub-id pub-id-type="pmid">16428759</pub-id></element-citation></ref><ref id="B88-viruses-10-00100"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skountzou</surname><given-names>I.</given-names></name><name><surname>Martin</surname><given-names>M.D.P.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Koutsonanos</surname><given-names>D.</given-names></name><name><surname>Weldon</surname><given-names>W.</given-names></name><name><surname>Jacob</surname><given-names>J.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>4103</fpage><lpage>4112</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.058</pub-id><?supplied-pmid 19654062?><pub-id pub-id-type="pmid">19654062</pub-id></element-citation></ref><ref id="B89-viruses-10-00100"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.R.</given-names></name><name><surname>Holbrook</surname><given-names>B.C.</given-names></name><name><surname>Hayward</surname><given-names>S.L.</given-names></name><name><surname>Blevins</surname><given-names>L.K.</given-names></name><name><surname>Jorgensen</surname><given-names>M.J.</given-names></name><name><surname>Kock</surname><given-names>N.D.</given-names></name><name><surname>De Paris</surname><given-names>K.</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>R.B.</given-names><suffix>Jr.</suffix></name><name><surname>Aycock</surname><given-names>S.T.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name><name><surname>Parks</surname><given-names>G.D.</given-names></name><name><surname>Alexander-Miller</surname><given-names>M.A.</given-names></name></person-group><article-title>Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>7291</fpage><lpage>7303</lpage><pub-id pub-id-type="doi">10.1128/JVI.00549-15</pub-id><?supplied-pmid 25948746?><pub-id pub-id-type="pmid">25948746</pub-id></element-citation></ref><ref id="B90-viruses-10-00100"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuadros</surname><given-names>C.</given-names></name><name><surname>Lopez-Hernandez</surname><given-names>F.J.</given-names></name><name><surname>Dominguez</surname><given-names>A.L.</given-names></name><name><surname>McClelland</surname><given-names>M.</given-names></name><name><surname>Lustgarten</surname><given-names>J.</given-names></name></person-group><article-title>Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>2810</fpage><lpage>2816</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.5.2810-2816.2004</pub-id><?supplied-pmid 15102791?><pub-id pub-id-type="pmid">15102791</pub-id></element-citation></ref><ref id="B91-viruses-10-00100"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>J.T.</given-names></name><name><surname>Uematsu</surname><given-names>S.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin</article-title><source>J. Immunol.</source><year>2009</year><volume>182</volume><fpage>7539</fpage><lpage>7547</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0804225</pub-id><?supplied-pmid 19494277?><pub-id pub-id-type="pmid">19494277</pub-id></element-citation></ref><ref id="B92-viruses-10-00100"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>C.J.</given-names></name><name><surname>Franchi</surname><given-names>L.</given-names></name><name><surname>Yarovinsky</surname><given-names>F.</given-names></name><name><surname>Uematsu</surname><given-names>S.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>G.</given-names></name><name><surname>Gewirtz</surname><given-names>A.T.</given-names></name></person-group><article-title>Induction of adaptive immunity by flagellin does not require robust activation of innate immunity</article-title><source>Eur. J. Immunol.</source><year>2009</year><volume>39</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1002/eji.200838804</pub-id><?supplied-pmid 19152336?><pub-id pub-id-type="pmid">19152336</pub-id></element-citation></ref><ref id="B93-viruses-10-00100"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letran</surname><given-names>S.E.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Atif</surname><given-names>S.M.</given-names></name><name><surname>Uematsu</surname><given-names>S.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name><name><surname>McSorley</surname><given-names>S.J.</given-names></name></person-group><article-title>TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunity</article-title><source>Eur. J. Immunol.</source><year>2011</year><volume>41</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/eji.201040717</pub-id><?supplied-pmid 21182074?><pub-id pub-id-type="pmid">21182074</pub-id></element-citation></ref><ref id="B94-viruses-10-00100"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>J.T.</given-names></name><name><surname>Graff</surname><given-names>A.H.</given-names></name><name><surname>Phipps</surname><given-names>J.P.</given-names></name><name><surname>Grayson</surname><given-names>J.M.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name></person-group><article-title>Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>6255</fpage><lpage>6262</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1001855</pub-id><?supplied-pmid 21515787?><pub-id pub-id-type="pmid">21515787</pub-id></element-citation></ref><ref id="B95-viruses-10-00100"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Yglesias</surname><given-names>A.H.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Quarles</surname><given-names>E.K.</given-names></name><name><surname>Lai</surname><given-names>M.A.</given-names></name><name><surname>VandenBos</surname><given-names>T.</given-names></name><name><surname>Strong</surname><given-names>R.K.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name></person-group><article-title>Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>1587</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301893</pub-id><?supplied-pmid 24442437?><pub-id pub-id-type="pmid">24442437</pub-id></element-citation></ref><ref id="B96-viruses-10-00100"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Vaccines: Correlates of vaccine-induced immunity</article-title><source>Clin. Infect. Dis.</source><year>2008</year><volume>47</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1086/589862</pub-id><?supplied-pmid 18558875?><pub-id pub-id-type="pmid">18558875</pub-id></element-citation></ref><ref id="B97-viruses-10-00100"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Correlates of protection induced by vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>1055</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id><?supplied-pmid 20463105?><pub-id pub-id-type="pmid">20463105</pub-id></element-citation></ref><ref id="B98-viruses-10-00100"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Hangartner</surname><given-names>L.</given-names></name></person-group><article-title>Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design</article-title><source>Annu. Rev. Immunol.</source><year>2016</year><volume>34</volume><fpage>635</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-041015-055515</pub-id><?supplied-pmid 27168247?><pub-id pub-id-type="pmid">27168247</pub-id></element-citation></ref><ref id="B99-viruses-10-00100"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadanand</surname><given-names>S.</given-names></name><name><surname>Suscovich</surname><given-names>T.J.</given-names></name><name><surname>Alter</surname><given-names>G.</given-names></name></person-group><article-title>Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design</article-title><source>Annu. Rev. Med.</source><year>2016</year><volume>67</volume><fpage>185</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-091014-090749</pub-id><?supplied-pmid 26565674?><pub-id pub-id-type="pmid">26565674</pub-id></element-citation></ref><ref id="B100-viruses-10-00100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montero</surname><given-names>M.</given-names></name><name><surname>van Houten</surname><given-names>N.E.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Scott</surname><given-names>J.K.</given-names></name></person-group><article-title>The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: Dominant site of antibody neutralization and target for vaccine design</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2008</year><volume>72</volume><fpage>54</fpage><lpage>84</lpage><comment>table of contents</comment><pub-id pub-id-type="doi">10.1128/MMBR.00020-07</pub-id><?supplied-pmid 18322034?><pub-id pub-id-type="pmid">18322034</pub-id></element-citation></ref><ref id="B101-viruses-10-00100"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hessell</surname><given-names>A.J.</given-names></name><name><surname>Rakasz</surname><given-names>E.G.</given-names></name><name><surname>Tehrani</surname><given-names>D.M.</given-names></name><name><surname>Huber</surname><given-names>M.</given-names></name><name><surname>Weisgrau</surname><given-names>K.L.</given-names></name><name><surname>Landucci</surname><given-names>G.</given-names></name><name><surname>Forthal</surname><given-names>D.N.</given-names></name><name><surname>Koff</surname><given-names>W.C.</given-names></name><name><surname>Poignard</surname><given-names>P.</given-names></name><name><surname>Watkins</surname><given-names>D.I.</given-names></name><etal/></person-group><article-title>Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>1302</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1128/JVI.01272-09</pub-id><?supplied-pmid 19906907?><pub-id pub-id-type="pmid">19906907</pub-id></element-citation></ref><ref id="B102-viruses-10-00100"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pegu</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>Z.-Y.</given-names></name><name><surname>Boyington</surname><given-names>J.C.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Ko</surname><given-names>S.-Y.</given-names></name><name><surname>Schmidt</surname><given-names>S.D.</given-names></name><name><surname>McKee</surname><given-names>K.</given-names></name><name><surname>Kong</surname><given-names>W.-P.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor</article-title><source>Sci. Transl. Med.</source><year>2014</year><volume>6</volume><fpage>243ra88</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3008992</pub-id><?supplied-pmid 24990883?><pub-id pub-id-type="pmid">24990883</pub-id></element-citation></ref><ref id="B103-viruses-10-00100"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pegu</surname><given-names>A.</given-names></name><name><surname>Hessell</surname><given-names>A.J.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Haigwood</surname><given-names>N.L.</given-names></name></person-group><article-title>Use of broadly neutralizing antibodies for HIV-1 prevention</article-title><source>Immunol. Rev.</source><year>2017</year><volume>275</volume><fpage>296</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/imr.12511</pub-id><?supplied-pmid 28133803?><pub-id pub-id-type="pmid">28133803</pub-id></element-citation></ref><ref id="B104-viruses-10-00100"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phogat</surname><given-names>S.</given-names></name><name><surname>Svehla</surname><given-names>K.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Spadaccini</surname><given-names>A.</given-names></name><name><surname>Muller</surname><given-names>J.</given-names></name><name><surname>Mascola</surname><given-names>J.</given-names></name><name><surname>Berkower</surname><given-names>I.</given-names></name><name><surname>Wyatt</surname><given-names>R.</given-names></name></person-group><article-title>Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles</article-title><source>Virology</source><year>2008</year><volume>373</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2007.11.005</pub-id><?supplied-pmid 18155743?><pub-id pub-id-type="pmid">18155743</pub-id></element-citation></ref><ref id="B105-viruses-10-00100"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venditto</surname><given-names>V.J.</given-names></name><name><surname>Wieczorek</surname><given-names>L.</given-names></name><name><surname>Molnar</surname><given-names>S.</given-names></name><name><surname>Teque</surname><given-names>F.</given-names></name><name><surname>Landucci</surname><given-names>G.</given-names></name><name><surname>Watson</surname><given-names>D.S.</given-names></name><name><surname>Forthal</surname><given-names>D.</given-names></name><name><surname>Polonis</surname><given-names>V.R.</given-names></name><name><surname>Levy</surname><given-names>J.A.</given-names></name><name><surname>Szoka</surname><given-names>F.C.</given-names></name></person-group><article-title>Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits</article-title><source>Clin. Vaccine Immunol.</source><year>2014</year><volume>21</volume><fpage>1086</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1128/CVI.00320-14</pub-id><?supplied-pmid 24872518?><pub-id pub-id-type="pmid">24872518</pub-id></element-citation></ref><ref id="B106-viruses-10-00100"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennison</surname><given-names>S.M.</given-names></name><name><surname>Sutherland</surname><given-names>L.L.</given-names></name><name><surname>Jaeger</surname><given-names>F.H.</given-names></name><name><surname>Anasti</surname><given-names>K.M.</given-names></name><name><surname>Parks</surname><given-names>R.</given-names></name><name><surname>Stewart</surname><given-names>S.</given-names></name><name><surname>Bowman</surname><given-names>C.</given-names></name><name><surname>Xia</surname><given-names>S.-M.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e27824</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0027824</pub-id><?supplied-pmid 22140469?><pub-id pub-id-type="pmid">22140469</pub-id></element-citation></ref><ref id="B107-viruses-10-00100"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strasz</surname><given-names>N.</given-names></name><name><surname>Morozov</surname><given-names>V.A.</given-names></name><name><surname>Kreutzberger</surname><given-names>J.</given-names></name><name><surname>Keller</surname><given-names>M.</given-names></name><name><surname>Eschricht</surname><given-names>M.</given-names></name><name><surname>Denner</surname><given-names>J.</given-names></name></person-group><article-title>Immunization with Hybrid Proteins Containing the Membrane Proximal External Region of HIV-1</article-title><source>AIDS Res. Hum. Retrovir.</source><year>2014</year><volume>30</volume><fpage>498</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1089/aid.2013.0191</pub-id><?supplied-pmid 24392780?><pub-id pub-id-type="pmid">24392780</pub-id></element-citation></ref><ref id="B108-viruses-10-00100"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Dong</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Bu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name></person-group><article-title>Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP Vaccines</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e14813</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0014813</pub-id><?supplied-pmid 21625584?><pub-id pub-id-type="pmid">21625584</pub-id></element-citation></ref><ref id="B109-viruses-10-00100"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venditto</surname><given-names>V.J.</given-names></name><name><surname>Watson</surname><given-names>D.S.</given-names></name><name><surname>Motion</surname><given-names>M.</given-names></name><name><surname>Montefiori</surname><given-names>D.</given-names></name><name><surname>Szoka</surname><given-names>F.C.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Rational Design of Membrane Proximal External Region Lipopeptides Containing Chemical Modifications for HIV-1 Vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1128/CVI.00615-12</pub-id><?supplied-pmid 23114698?><pub-id pub-id-type="pmid">23114698</pub-id></element-citation></ref><ref id="B110-viruses-10-00100"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Patrick</surname><given-names>A.J.</given-names></name><name><surname>Rosenthal</surname><given-names>K.L.</given-names></name></person-group><article-title>Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>7070</fpage><lpage>7080</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.009</pub-id><?supplied-pmid 20723627?><pub-id pub-id-type="pmid">20723627</pub-id></element-citation></ref><ref id="B111-viruses-10-00100"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhai</surname><given-names>Y.</given-names></name><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Zariffard</surname><given-names>M.</given-names></name><name><surname>Spear</surname><given-names>G.T.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name></person-group><article-title>Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>5422</fpage><lpage>5429</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.003</pub-id><?supplied-pmid 24055348?><pub-id pub-id-type="pmid">24055348</pub-id></element-citation></ref><ref id="B112-viruses-10-00100"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>G.</given-names></name><name><surname>Lapelosa</surname><given-names>M.</given-names></name><name><surname>Bradley</surname><given-names>R.</given-names></name><name><surname>Mariano</surname><given-names>T.M.</given-names></name><name><surname>Dietz</surname><given-names>D.E.</given-names></name><name><surname>Hughes</surname><given-names>S.</given-names></name><name><surname>Wrin</surname><given-names>T.</given-names></name><name><surname>Petropoulos</surname><given-names>C.</given-names></name><name><surname>Gallicchio</surname><given-names>E.</given-names></name><name><surname>Levy</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e72205</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/57fc0148-19fe-4b8b-b2f4-bb5f60baa971</pub-id><?supplied-pmid 24116242?><pub-id pub-id-type="pmid">24039745</pub-id></element-citation></ref><ref id="B113-viruses-10-00100"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehme</surname><given-names>K.W.</given-names></name><name><surname>Ikizler</surname><given-names>M.</given-names></name><name><surname>Iskarpatyoti</surname><given-names>J.A.</given-names></name><name><surname>Wetzel</surname><given-names>J.D.</given-names></name><name><surname>Willis</surname><given-names>J.</given-names></name><name><surname>Crowe</surname><given-names>J.E.</given-names></name><name><surname>LaBranche</surname><given-names>C.C.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Wilson</surname><given-names>G.J.</given-names></name><name><surname>Dermody</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1</article-title><source>mSphere</source><year>2016</year><volume>1</volume><fpage>e00086-16</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00086-16</pub-id><?supplied-pmid 27303748?><pub-id pub-id-type="pmid">27303748</pub-id></element-citation></ref><ref id="B114-viruses-10-00100"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinos-Albert</surname><given-names>L.M.</given-names></name><name><surname>Bilbao</surname><given-names>E.</given-names></name><name><surname>Agull&#x000f3;</surname><given-names>L.</given-names></name><name><surname>Marfil</surname><given-names>S.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>E.</given-names></name><name><surname>de Concepci&#x000f3;n</surname><given-names>M.L.R.L.</given-names></name><name><surname>Izquierdo-Useros</surname><given-names>N.</given-names></name><name><surname>Vilaplana</surname><given-names>C.</given-names></name><name><surname>Nieto-Garai</surname><given-names>J.A.</given-names></name><name><surname>Contreras</surname><given-names>F.X.</given-names></name><etal/></person-group><article-title>Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>40800</fpage><pub-id pub-id-type="doi">10.1038/srep40800</pub-id><?supplied-pmid 28084464?><pub-id pub-id-type="pmid">28084464</pub-id></element-citation></ref><ref id="B115-viruses-10-00100"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><name><surname>Moon</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Z.-Y.J.</given-names></name><name><surname>Bershteyn</surname><given-names>A.</given-names></name><name><surname>Hanson</surname><given-names>M.</given-names></name><name><surname>Cain</surname><given-names>D.</given-names></name><name><surname>Goka</surname><given-names>S.</given-names></name><name><surname>Kelsoe</surname><given-names>G.</given-names></name><name><surname>Wagner</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>31888</fpage><lpage>31901</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.494609</pub-id><?supplied-pmid 24047898?><pub-id pub-id-type="pmid">24047898</pub-id></element-citation></ref><ref id="B116-viruses-10-00100"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>C.</given-names></name><name><surname>Schaarschmidt</surname><given-names>P.</given-names></name><name><surname>Engel</surname><given-names>A.M.</given-names></name><name><surname>Andres</surname><given-names>H.</given-names></name><name><surname>Schmitt</surname><given-names>U.</given-names></name><name><surname>Faatz</surname><given-names>E.</given-names></name><name><surname>Balbach</surname><given-names>J.</given-names></name><name><surname>Schmid</surname><given-names>F.X.</given-names></name></person-group><article-title>Functional Solubilization of Aggregation-prone HIV Envelope Proteins by Covalent Fusion with Chaperone Modules</article-title><source>J. Mol. Biol.</source><year>2005</year><volume>345</volume><fpage>1229</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.10.091</pub-id><?supplied-pmid 15644217?><pub-id pub-id-type="pmid">15644217</pub-id></element-citation></ref><ref id="B117-viruses-10-00100"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enshell-Seijffers</surname><given-names>D.</given-names></name><name><surname>Smelyanski</surname><given-names>L.</given-names></name><name><surname>Vardinon</surname><given-names>N.</given-names></name><name><surname>Yust</surname><given-names>I.</given-names></name><name><surname>Gershoni</surname><given-names>J.M.</given-names></name></person-group><article-title>Dissection of the humoral immune response toward an immunodominant epitope of HIV: A model for the analysis of antibody diversity in HIV+ individuals</article-title><source>FASEB J.</source><year>2001</year><volume>15</volume><fpage>2112</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1096/fj.00-0898com</pub-id><?supplied-pmid 11641237?><pub-id pub-id-type="pmid">11641237</pub-id></element-citation></ref><ref id="B118-viruses-10-00100"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinos-Albert</surname><given-names>L.M.</given-names></name><name><surname>Carrillo</surname><given-names>J.</given-names></name><name><surname>Curriu</surname><given-names>M.</given-names></name><name><surname>de la Concepci&#x000f3;n</surname><given-names>M.L.R.</given-names></name><name><surname>Marfil</surname><given-names>S.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>E.</given-names></name><name><surname>Clotet</surname><given-names>B.</given-names></name><name><surname>Blanco</surname><given-names>J.</given-names></name></person-group><article-title>Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals</article-title><source>Retrovirology</source><year>2014</year><volume>11</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-11-44</pub-id><?supplied-pmid 24909946?><pub-id pub-id-type="pmid">24909946</pub-id></element-citation></ref><ref id="B119-viruses-10-00100"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>B.F.</given-names></name><name><surname>Fleming</surname><given-names>J.</given-names></name><name><surname>Clair</surname><given-names>E.W.S.</given-names></name><name><surname>Katinger</surname><given-names>H.</given-names></name><name><surname>Stiegler</surname><given-names>G.</given-names></name><name><surname>Kunert</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>J.</given-names></name><name><surname>Scearce</surname><given-names>R.M.</given-names></name><name><surname>Plonk</surname><given-names>K.</given-names></name><name><surname>Staats</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1906</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1126/science.1111781</pub-id><?supplied-pmid 15860590?><pub-id pub-id-type="pmid">15860590</pub-id></element-citation></ref><ref id="B120-viruses-10-00100"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Frey</surname><given-names>G.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Rits-Volloch</surname><given-names>S.</given-names></name><name><surname>Garrity</surname><given-names>J.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1249</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1128/JVI.02664-13</pub-id><?supplied-pmid 24227838?><pub-id pub-id-type="pmid">24227838</pub-id></element-citation></ref><ref id="B121-viruses-10-00100"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnychuk</surname><given-names>L.</given-names></name><name><surname>Ajamian</surname><given-names>L.</given-names></name><name><surname>Jean-Pierre</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Gheorghe</surname><given-names>R.</given-names></name><name><surname>Wainberg</surname><given-names>M.A.</given-names></name><name><surname>Zaharatos</surname><given-names>G.J.</given-names></name></person-group><article-title>Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>2736</fpage><lpage>2744</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.03.039</pub-id><?supplied-pmid 28392143?><pub-id pub-id-type="pmid">28392143</pub-id></element-citation></ref><ref id="B122-viruses-10-00100"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Howard</surname><given-names>A.</given-names></name><name><surname>Kelley</surname><given-names>C.</given-names></name><name><surname>Delogu</surname><given-names>G.</given-names></name><name><surname>Collins</surname><given-names>F.</given-names></name><name><surname>Morris</surname><given-names>S.</given-names></name></person-group><article-title>Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences</article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>4780</fpage><lpage>4786</lpage><?supplied-pmid 10456931?><pub-id pub-id-type="pmid">10456931</pub-id></element-citation></ref><ref id="B123-viruses-10-00100"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>S.M.</given-names></name></person-group><article-title>Flagellar glycosylation&#x02014;A new component of the motility repertoire?</article-title><source>Microbiology</source><year>2006</year><volume>152</volume><fpage>1249</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1099/mic.0.28735-0</pub-id><?supplied-pmid 16622043?><pub-id pub-id-type="pmid">16622043</pub-id></element-citation></ref><ref id="B124-viruses-10-00100"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><?supplied-pmid 21616434?><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="B125-viruses-10-00100"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2015</year><volume>7</volume><fpage>a016246</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a016246</pub-id><?supplied-pmid 25301932?><pub-id pub-id-type="pmid">25301932</pub-id></element-citation></ref><ref id="B126-viruses-10-00100"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen-Nissen</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>K.D.</given-names></name><name><surname>Bonneau</surname><given-names>R.</given-names></name><name><surname>Strong</surname><given-names>R.K.</given-names></name><name><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin</article-title><source>J. Exp. Med.</source><year>2007</year><volume>204</volume><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1084/jem.20061400</pub-id><?supplied-pmid 17283206?><pub-id pub-id-type="pmid">17283206</pub-id></element-citation></ref><ref id="B127-viruses-10-00100"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S.</given-names></name><name><surname>Takeshita</surname><given-names>F.</given-names></name><name><surname>Matsuda</surname><given-names>T.</given-names></name><name><surname>Jounai</surname><given-names>N.</given-names></name><name><surname>Kobiyama</surname><given-names>K.</given-names></name><name><surname>Matsumoto</surname><given-names>T.</given-names></name><name><surname>Sasaki</surname><given-names>S.</given-names></name><name><surname>Yoshida</surname><given-names>A.</given-names></name><name><surname>Xin</surname><given-names>K.-Q.</given-names></name><name><surname>Klinman</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine</article-title><source>J. Immunol.</source><year>2007</year><volume>179</volume><fpage>1147</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.179.2.1147</pub-id><?supplied-pmid 17617608?><pub-id pub-id-type="pmid">17617608</pub-id></element-citation></ref><ref id="B128-viruses-10-00100"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forstneri&#x0010d;</surname><given-names>V.</given-names></name><name><surname>Ivi&#x0010d;ak-Kocjan</surname><given-names>K.</given-names></name><name><surname>Ljubeti&#x0010d;</surname><given-names>A.</given-names></name><name><surname>Jerala</surname><given-names>R.</given-names></name><name><surname>Ben&#x0010d;ina</surname><given-names>M.</given-names></name></person-group><article-title>Distinctive Recognition of Flagellin by Human and Mouse Toll-Like Receptor</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0158894</elocation-id><pub-id pub-id-type="pmid">27391968</pub-id></element-citation></ref><ref id="B129-viruses-10-00100"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Puckett</surname><given-names>S.</given-names></name><name><surname>Arimilli</surname><given-names>S.</given-names></name><name><surname>Braxton</surname><given-names>C.L.</given-names></name><name><surname>Mizel</surname><given-names>S.B.</given-names></name><name><surname>Lyles</surname><given-names>D.S.</given-names></name></person-group><article-title>Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>12093</fpage><lpage>12098</lpage><pub-id pub-id-type="doi">10.1128/JVI.00406-10</pub-id><?supplied-pmid 20844045?><pub-id pub-id-type="pmid">20844045</pub-id></element-citation></ref><ref id="B130-viruses-10-00100"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>M.L.</given-names></name><name><surname>Johansson</surname><given-names>D.X.</given-names></name><name><surname>Kostic</surname><given-names>L.</given-names></name><name><surname>Nordstr&#x000f6;m</surname><given-names>E.K.L.</given-names></name><name><surname>Tegerstedt</surname><given-names>K.</given-names></name><name><surname>Pasetto</surname><given-names>A.</given-names></name><name><surname>Applequist</surname><given-names>S.E.</given-names></name><name><surname>Ljungberg</surname><given-names>K.</given-names></name><name><surname>Sirard</surname><given-names>J.-C.</given-names></name><name><surname>Liljestr&#x000f6;m</surname><given-names>P.</given-names></name></person-group><article-title>The Adjuvant Activity of Alphavirus Replicons Is Enhanced by Incorporating the Microbial Molecule Flagellin into the Replicon</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e65964</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0065964</pub-id><?supplied-pmid 23785460?><pub-id pub-id-type="pmid">23785460</pub-id></element-citation></ref><ref id="B131-viruses-10-00100"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rady</surname><given-names>H.F.</given-names></name><name><surname>Dai</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Shellito</surname><given-names>J.E.</given-names></name><name><surname>Ramsay</surname><given-names>A.J.</given-names></name></person-group><article-title>Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0148701</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148701</pub-id><?supplied-pmid 26844553?><pub-id pub-id-type="pmid">26844553</pub-id></element-citation></ref><ref id="B132-viruses-10-00100"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikic</surname><given-names>I.</given-names></name></person-group><article-title>Proteasomal and Autophagic Degradation Systems</article-title><source>Annu. Rev. Biochem.</source><year>2017</year><volume>86</volume><fpage>193</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-061516-044908</pub-id><?supplied-pmid 28460188?><pub-id pub-id-type="pmid">28460188</pub-id></element-citation></ref><ref id="B133-viruses-10-00100"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonderviszt</surname><given-names>F.</given-names></name><name><surname>Kanto</surname><given-names>S.</given-names></name><name><surname>Aizawa</surname><given-names>S.</given-names></name><name><surname>Namba</surname><given-names>K.</given-names></name></person-group><article-title>Terminal regions of flagellin are disordered in solution</article-title><source>J. Mol. Biol.</source><year>1989</year><volume>209</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(89)90176-9</pub-id><pub-id pub-id-type="pmid">2810365</pub-id></element-citation></ref><ref id="B134-viruses-10-00100"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>S.M.C.</given-names></name><name><surname>Joys</surname><given-names>T.M.</given-names></name><name><surname>Anderson</surname><given-names>S.A.</given-names></name><name><surname>Kennedy</surname><given-names>R.C.</given-names></name><name><surname>Hovi</surname><given-names>M.E.</given-names></name><name><surname>Stocker</surname><given-names>B.A.D.</given-names></name></person-group><article-title>Expression and immunogenicity of an 18-residue epitope of HIV1 gp41 inserted in the flagellar protein of a Salmonella live vaccine</article-title><source>Res. Microbiol.</source><year>1995</year><volume>146</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/0923-2508(96)80276-2</pub-id><pub-id pub-id-type="pmid">7569315</pub-id></element-citation></ref><ref id="B135-viruses-10-00100"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattozzo</surname><given-names>E.M.</given-names></name><name><surname>Stocker</surname><given-names>B.A.D.</given-names></name><name><surname>Radaelli</surname><given-names>A.</given-names></name><name><surname>De Giuli Morghen</surname><given-names>C.</given-names></name><name><surname>Tognon</surname><given-names>M.</given-names></name></person-group><article-title>Expression and immunogenicity of V3 loop epitopes of HIV-1, isolates SC and WMJ2, inserted in Salmonella flagellin</article-title><source>J. Biotechnol.</source><year>1997</year><volume>56</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/S0168-1656(97)00117-X</pub-id><pub-id pub-id-type="pmid">9304878</pub-id></element-citation></ref><ref id="B136-viruses-10-00100"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilieva</surname><given-names>E.V.</given-names></name><name><surname>Wang</surname><given-names>B.-Z.</given-names></name><name><surname>Vzorov</surname><given-names>A.N.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.-C.</given-names></name><name><surname>Bozja</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Compans</surname><given-names>R.W.</given-names></name></person-group><article-title>Enhanced Mucosal Immune Responses to HIV Virus-Like Particles Containing a Membrane-Anchored Adjuvant</article-title><source>mBio</source><year>2010</year><volume>2</volume><fpage>e00328-10</fpage><pub-id pub-id-type="doi">10.1128/mBio.00328-10</pub-id><?supplied-pmid 21325038?><pub-id pub-id-type="pmid">21325038</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="viruses-10-00100-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Domain structure of full-length flagellin. Image derived from PDB ID: 1UCU [<xref rid="B38-viruses-10-00100" ref-type="bibr">38</xref>] visualized with iCn3D (<uri xlink:href="https://www.ncbi.nlm.nih.gov/Structure/icn3d/full.html">https://www.ncbi.nlm.nih.gov/Structure/icn3d/full.html</uri>) and modified to indicate D0, D1, D2 and D3 domains. Residues 89&#x02013;96 (QRVRELAV) in the D1 domain are encircled by a red dashed line.</p></caption><graphic xlink:href="viruses-10-00100-g001"/></fig><fig id="viruses-10-00100-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>FliC constructs expressed in a mammalian system are secreted and maintain Toll-like receptor 5 (TLR5) agonist activity. (<bold>A</bold>) Schematic representation of flagellin (FliC) constructs; (<bold>B</bold>) Western blot of cell lysates, supernatants and PNGase F treated supernatants from transiently transfected 293T. Cells were transfected with pVAX (empty vector), FliC, FliC &#x00394;174&#x02013;400 or FliC &#x00394;220&#x02013;320. Samples were collected 48 h post transfection. Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (<bold>C</bold>) Measurement of relative secretion level of FLAG-tagged proteins using capture ELISA. Supernatants from transiently transfected 293T were applied to anti-FLAG tag antibody coated plates and probed with a horseradish peroxidase (HRP) conjugated mouse anti-FLAG tag antibody. Results shown represent the mean of 4 different experiments where FliC is set to a value of 1. Error bars represent standard error of the mean; (<bold>D</bold>) Relative TLR5 agonist activity of secreted FliC proteins. Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. After 20 h incubation, the quantity of secreted embryonic alkaline phosphatase (SEAP) produced was determined using a colorimetric enzyme assay. Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. Results shown represent the mean of 4 different experiments where pVAX is set to a value of 1. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="viruses-10-00100-g002"/></fig><fig id="viruses-10-00100-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Residues QRVRELAV (89&#x02013;96) of FliC are required for TLR5 agonist activity. (<bold>A</bold>) Schematic representation of FliC constructs; (<bold>B</bold>) Western blots of cell lysates and supernatants from transiently transfected 293T. Cells were transfected with pVAX, FliC, FliC &#x00394;174&#x02013;400, FliC &#x00394;220&#x02013;320, FliC &#x00394;89&#x02013;96, FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 or FliC &#x00394;89&#x02013;96 &#x00394;220&#x02013;320. Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (<bold>C</bold>) Relative TLR5 agonist activity of secreted FliC proteins. Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. After 20 h incubation, the quantity of SEAP produced was determined using a colorimetric enzyme assay. Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. Results shown represent the mean of 4 different experiments where pVAX is set to a value of 1. Error bars represent standard error of the mean; (<bold>D</bold>) Induction of IL-1&#x003b2; transcription detected by RT-PCR and gel electrophoresis. Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to THP-1 or J774A.1 cells. Cells were incubated for 2 h then harvested and RNA was obtained for RT-PCR with IL-1&#x003b2; specific primers. Cells treated with LPS or with supernatant from empty vector transfected cells were used as induced and non-induced controls, respectively. RT-PCR with GAPDH specific primers was used as an internal control. To exclude potential DNA carry-over and amplification or contamination, control reactions omitting the RT enzyme (-RT) or omitting input RNA (negative control) are also shown.</p></caption><graphic xlink:href="viruses-10-00100-g003"/></fig><fig id="viruses-10-00100-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>FliC &#x00394;174-400 with gp41<sub>607-683</sub> inserted at its N-terminus is secreted and maintains TLR5 agonist activity. (<bold>A</bold>) Schematic representation of flagellin constructs; (<bold>B</bold>) Western blot of cell lysates and supernatants from transiently transfected 293T. Cells were transfected with pVAX, FliC, FliC &#x00394;174&#x02013;400, FliC &#x00394;220&#x02013;320, gp41<sub>607&#x02013;683</sub> FliC, gp41<sub>607&#x02013;683</sub> FliC &#x00394;174&#x02013;400, gp41<sub>607&#x02013;683</sub> FliC &#x00394;220&#x02013;320, FliC &#x00394;174-[gp41<sub>607&#x02013;683</sub>]-400, FliC &#x00394;220-[gp41<sub>607&#x02013;683</sub>]-320, FliC gp41<sub>607&#x02013;683</sub>, FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or FliC &#x00394;220&#x02013;320 gp41<sub>607&#x02013;683</sub>. Samples were collected 48 h post transfection. Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (<bold>C</bold>) Measurement of relative secretion level of FLAG-tagged proteins using capture ELISA. Supernatants from transiently transfected 293T were applied to anti-FLAG tag antibody coated plates and probed with an HRP conjugated mouse anti-FLAG tag antibody. Results shown represent the mean of 3 different experiments where FliC is set to a value of 1. Error bars represent standard error of the mean; (<bold>D</bold>) Relative TLR5 agonist activity of secreted FliC proteins. Normalized supernatants from transiently transfected 293T were diluted 1:100 and added to HEK-Blue-hTLR5 cells. After 20 h incubation, the quantity of SEAP produced was determined using a colorimetric enzyme assay. Relative quantities, presented as response ratios, are indicative of TLR5 agonist activity. Results shown represent the mean of 3 different experiments where pVAX is set to a value of 1. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="viruses-10-00100-g004a"/><graphic xlink:href="viruses-10-00100-g004b"/></fig><fig id="viruses-10-00100-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> and gp41<sub>607&#x02013;683</sub> have similar gp41 antigenicity. (<bold>A</bold>) Western blot of cell lysates, supernatants and PNGase F treated supernatants from transiently transfected 293T. Cells were transfected with pVAX, FliC &#x00394;174&#x02013;400, FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or gp41<sub>607&#x02013;683</sub>. Samples were collected 48 h post transfection. Blots were probed with a mouse anti-FLAG tag antibody to detect FLAG-tagged flagellin proteins. A mouse anti-tubulin antibody, was used to detect tubulin as a loading control; (<bold>B</bold>) Schematic representation of 4E10 and 10E8 binding sites; (<bold>C</bold>) Binding of MPER-specific broadly neutralizing antibodies (bnAB) to FliC &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> and gp41<sub>607&#x02013;683</sub>. Normalized supernatants from transiently transfected 293T were added to streptavidin coated plates. Captured antigen was probed with either 10E8 or 4E10 antibodies, then an AP-conjugated mouse anti-human IgG secondary antibody was used to detect antigen-bound 10E8 and 4E10. Binding was measured using a fluorescent AP substrate assay and further normalized to levels of captured antigen in each well. Results shown represent the mean of 3 different experiments where gp41<sub>607&#x02013;683</sub> is set to a value of 1. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="viruses-10-00100-g005"/></fig><fig id="viruses-10-00100-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>FliC&#x00394;174&#x02013;400 augments HIV-1 gp41<sub>607&#x02013;683</sub> immunogenicity. (<bold>A</bold>) Detection of HIV-1 gp41<sub>607&#x02013;683</sub> binding antibodies in vaccinated mice. Female BALB/c mice (10 mice per experimental arm) were injected intramuscularly with either pVAX (empty vector) or DNA vaccines FliC&#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or gp41<sub>607&#x02013;683</sub> (50 &#x003bc;L in each hind leg at a concentration of 1 &#x003bc;g/&#x003bc;L). Two weeks following the 4th vaccination, mouse serum (1:200 dilution) was analyzed for a gp41<sub>607&#x02013;683</sub> specific IgG response. Each point represents the mean absorbance value obtained from individual mouse serum (each analyzed in duplicate). Horizontal bars represent average values per vaccine group and error bars represent +/&#x02212; standard error of the mean. Significance was determined using an unpaired <italic>t</italic>-test with ** indicating a <italic>p</italic> value &#x0003c; 0.01; (<bold>B</bold>) Detection of antibodies binding C-terminal residues of HIV-1 gp41<sub>607&#x02013;683</sub>. Mouse sera from the mice vaccinated with FliC&#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> were analyzed for an MPER-specific IgG response by comparing binding to gp41<sub>607&#x02013;683</sub> (containing the entire MPER) and gp41<sub>607&#x02013;671</sub> (lacking the twelve C-terminal residues of MPER). Vertical bars graphs represent the mean absorbance value obtained for pooled sera (<italic>n</italic> = 10 mice) analyzed in duplicate. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="viruses-10-00100-g006"/></fig><fig id="viruses-10-00100-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Deletion of FliC residues 89&#x02013;96 results in a reduced adjuvant effect on HIV-1 gp41<sub>607&#x02013;683</sub> immunogenicity. Female BALB/c mice (10 mice per experimental arm) were injected intramuscularly with either pVAX (empty vector) or DNA vaccines FliC&#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> or FliC &#x00394;89&#x02013;96 &#x00394;174&#x02013;400 gp41<sub>607&#x02013;683</sub> (50 &#x003bc;L in each hind leg at a concentration of 1 &#x003bc;g/&#x003bc;L). Two weeks following the 4th vaccination, mouse serum (1:200 dilution) was analyzed for a gp41<sub>607&#x02013;683</sub> specific IgG response. Each point represents the mean absorbance value obtained from individual mouse serum (each with two replicates per mouse). Horizontal bars represent average values per vaccine group and error bars represent standard error of the mean. Significance was determined using an unpaired <italic>t</italic>-test with ** indicating a <italic>p</italic> value &#x0003c; 0.01.</p></caption><graphic xlink:href="viruses-10-00100-g007"/></fig></floats-group></article>